These	O
committed	O
lymphoid	O
cells	O
must	O
then	O
undergo	O
V	O
(	O
D	O
)	O
J	O
recombination	O
at	O
the	O
immunoglobulin	O
gene	O
or	O
T	O
cell	O
receptor	O
gene	O
locus	O
resulting	O
in	O
clonal	O
production	O
of	O
functional	O
B	O
or	O
T	O
lymphocytes	O
,	O
respectively	O
.	O
Lymphocyte	O
commitment	O
and	O
differentiation	O
are	O
accompanied	O
by	O
programmed	O
gene	O
expression	O
or	O
repression	O
events	O
which	O
are	O
driven	O
by	O
lineage	O
and	O
stage	O
specific	O
transcription	B-protein
factors	I-protein
.	O
The	O
basic-helix-loop-helix	B-protein
(	I-protein
bHLH	I-protein
)	I-protein
transcription	I-protein
factors	I-protein
encoded	O
by	O
the	O
E2A	O
gene	O
are	O
involved	O
in	O
several	O
differentiation	O
events	O
during	O
B	O
and	O
T	O
cell	O
development	O
,	O
including	O
lineage	O
commitment	O
,	O
initiation	O
of	O
V	O
(	O
D	O
)	O
J	O
recombination	O
,	O
and	O
antigen	O
receptor	O
mediated	O
proliferation	O
and	O
differentiation	O
.	O
Several	O
recent	O
reviews	O
have	O
provided	O
a	O
comprehensive	O
discussion	O
of	O
biochemical	O
,	O
cellular	O
,	O
and	O
genetic	O
research	O
on	O
E2A	O
function	O
in	O
lymphocyte	O
development	O
(	O
1	O
,	O
2	O
)	O
.	O
Here	O
,	O
we	O
only	O
discuss	O
some	O
of	O
the	O
genetic	O
approaches	O
our	O
laboratory	O
(	O
except	O
where	O
it	O
is	O
noted	O
)	O
has	O
undertaken	O
to	O
investigate	O
the	O
molecular	O
pathways	O
mediated	O
by	O
E2A	B-protein
transcription	I-protein
factors	I-protein
in	O
lymphocyte	O
development	O
D609	O
inhibits	O
ionizing	O
radiation-induced	O
oxidative	O
damage	O
by	O
acting	O
as	O
a	O
potent	O
antioxidant	O
.	O
Tricyclodecan-9-yl-xanthogenate	O
(	O
D609	O
)	O
has	O
been	O
extensively	O
studied	O
in	O
biological	O
systems	O
and	O
exhibits	O
a	O
variety	O
of	O
biological	O
functions	O
,	O
including	O
antiviral	O
,	O
antitumor	O
,	O
and	O
anti-inflammatory	O
activities	O
.	O
Most	O
of	O
these	O
activities	O
have	O
been	O
largely	O
attributed	O
to	O
the	O
inhibitory	O
effect	O
of	O
D609	O
on	O
phosphatidylcholine-specific	B-protein
phospholipase	I-protein
C	I-protein
.	O
However	O
,	O
as	O
a	O
xanthate	O
derivative	O
,	O
D609	B-protein
is	O
a	O
strong	O
electrolyte	O
and	O
readily	O
dissociates	O
to	O
xanthate	O
anions	O
and	O
cations	O
of	O
alkali	O
metals	O
in	O
solution	O
.	O
Xanthate	O
anions	O
and	O
protonated	O
xanthic	O
acid	O
contain	O
a	O
free	O
thiol	O
moiety	O
and	O
are	O
highly	O
reductive	O
.	O
This	O
implies	O
that	O
D609	O
and	O
other	O
xanthate	O
derivatives	O
may	O
function	O
as	O
potent	O
antioxidants	O
.	O
Indeed	O
,	O
we	O
found	O
that	O
D609	B-protein
inhibited	O
the	O
Fenton	O
reaction-induced	O
oxidation	O
of	O
dihydrorhodamine	O
123	O
in	O
a	O
dose-dependent	O
manner	O
similar	O
to	O
that	O
of	O
pyrrolidinedithiocarbamate	O
,	O
a	O
well	O
known	O
antioxidant	O
.	O
In	O
addition	O
,	O
D609	B-protein
inhibited	O
the	O
formation	O
of	O
the	O
alpha-phenyl-tert-butylnitrone-free	O
radical	O
spin	O
adducts	O
and	O
lipid	O
peroxidation	O
of	O
synaptosomal	O
membranes	O
by	O
the	O
Fenton	O
reagents	O
.	O
Furthermore	O
,	O
preincubation	O
of	O
lymphocytes	O
with	O
D609	O
resulted	O
in	O
a	O
significant	O
diminution	O
of	O
ionizing	O
radiation	O
(	O
IR	O
)	O
-induced	O
1	O
)	O
production	O
of	O
reactive	O
oxygen	O
species	O
;	O
2	O
)	O
decrease	O
in	O
intracellular	O
reduced	O
glutathione	O
;	O
3	O
)	O
oxidative	O
damage	O
to	O
proteins	O
and	O
lipids	O
;	O
and	O
4	O
)	O
activation	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
.	O
Moreover	O
,	O
when	O
D609	O
(	O
50	O
mg/kg	O
)	O
was	O
administered	O
to	O
mice	O
10	O
min	O
prior	O
to	O
total	O
body	O
IR	O
(	O
6.5	O
and	O
8.5	O
Gy	O
)	O
,	O
it	O
protected	O
the	O
mice	O
from	O
IR-induced	O
lethality	O
.	O
Thus	O
,	O
these	O
results	O
indicate	O
that	O
D609	B-protein
is	O
a	O
potent	O
antioxidant	O
and	O
has	O
the	O
ability	O
to	O
inhibit	O
IR-induced	O
cellular	O
oxidative	O
stress	O
.	O
Inhibition	O
of	O
AP-1	B-protein
by	O
the	O
glucocorticoid-inducible	B-protein
protein	I-protein
GILZ	I-protein
.	O
The	O
immunosuppressive	O
effects	O
of	O
glucocorticoids	O
arise	O
largely	O
by	O
inhibition	O
of	O
cytokine	O
gene	O
expression	O
,	O
which	O
has	O
been	O
ascribed	O
to	O
interference	O
between	O
the	O
glucocorticoid	B-protein
receptor	I-protein
and	O
transcription	B-protein
factors	I-protein
such	O
as	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
as	O
well	O
as	O
by	O
competition	O
for	O
common	O
coactivators	O
.	O
Here	O
we	O
show	O
that	O
glucocorticoid-induced	O
inhibition	O
of	O
interleukin-2	O
mRNA	O
expression	O
in	O
activated	O
normal	O
T	O
cells	O
required	O
new	O
protein	O
synthesis	O
,	O
suggesting	O
that	O
this	O
phenomenon	O
is	O
secondary	O
to	O
expression	O
of	O
glucocorticoid-regulated	O
genes	O
.	O
One	O
of	O
the	O
most	O
prominent	O
glucocorticoid-induced	O
genes	O
is	O
glucocorticoid-induced	O
leucine	O
zipper	O
(	O
GILZ	O
)	O
,	O
which	O
has	O
been	O
reported	O
to	O
inhibit	O
activation-induced	O
up-regulation	O
of	O
Fas	B-protein
ligand	I-protein
(	O
FasL	B-protein
)	O
mRNA	O
.	O
Indeed	O
,	O
transient	O
expression	O
of	O
GILZ	O
in	O
Jurkat	O
T	O
cells	O
blocked	O
induction	O
of	O
a	O
reporter	O
construct	O
driven	O
by	O
the	O
FasL	O
promoter	O
.	O
This	O
could	O
be	O
accounted	O
for	O
by	O
GILZ	B-protein
-mediated	O
inhibition	O
of	O
Egr-2	O
and	O
Egr-3	O
,	O
NFAT/AP-1	O
-inducible	O
transcription	O
factors	O
that	O
bind	O
a	O
regulatory	O
element	O
in	O
the	O
FasL	O
promoter	O
and	O
up-regulate	O
FasL	O
expression	O
.	O
GILZ	O
also	O
potently	O
inhibited	O
AP-1-driven	O
and	O
IL-2	O
promoter-driven	O
reporter	O
constructs	O
,	O
and	O
recombinant	B-protein
GILZ	I-protein
specifically	O
interacted	O
with	O
c-Fos	B-protein
and	O
c-Jun	B-protein
in	O
vitro	O
and	O
inhibited	O
the	O
binding	O
of	O
active	O
AP-1	B-protein
to	O
its	O
target	O
DNA	O
.	O
Whereas	O
homodimerization	O
of	O
GILZ	B-protein
required	O
the	O
presence	O
of	O
its	O
leucine	O
zipper	O
,	O
the	O
interaction	O
with	O
c-Fos	B-protein
and	O
c-Jun	B-protein
occurred	O
through	O
the	O
N-terminal	O
60-amino	O
acid	O
region	O
of	O
GILZ	O
.	O
Thus	O
,	O
GILZ	O
represents	O
a	O
glucocorticoid-induced	O
gene	O
product	O
that	O
can	O
inhibit	O
a	O
variety	O
of	O
activation-induced	O
events	O
,	O
at	O
least	O
in	O
part	O
by	O
direct	O
interference	O
with	O
AP-1	B-protein
,	O
and	O
is	O
therefore	O
a	O
candidate	O
for	O
a	O
mediator	O
of	O
glucocorticoid-induced	O
immunosuppression	O
.	O
Pharmacokinetic	O
differences	O
between	O
a	O
T	O
cell-tolerizing	O
and	O
a	O
T	O
cell-activating	O
peptide	O
.	O
Vaccination	O
with	O
a	O
peptide	O
representing	O
a	O
CTL	O
epitope	O
from	O
the	O
human	O
papillomavirus	O
(	O
HPV	B-protein
)	I-protein
16	I-protein
E7	I-protein
protein	I-protein
induces	O
a	O
specific	O
CTL	O
response	O
that	O
prevents	O
the	O
outgrowth	O
of	O
HPV16	O
E7-expressing	O
tumors	O
.	O
In	O
contrast	O
,	O
vaccination	O
with	O
a	O
peptide	O
encoding	O
an	O
adenovirus	O
type	O
5	O
(	O
Ad5	O
)	O
E1A	O
CTL	O
epitope	O
results	O
in	O
CTL	O
tolerance	O
and	O
enhanced	O
growth	O
of	O
an	O
Ad5	O
E1A-expressing	O
tumor	O
.	O
It	O
is	O
unclear	O
why	O
these	O
peptides	O
induce	O
such	O
opposite	O
effects	O
.	O
To	O
determine	O
whether	O
a	O
difference	O
in	O
pharmacokinetics	O
can	O
explain	O
the	O
functional	O
contrasts	O
,	O
tritiated	O
Ad5	O
E1A	O
and	O
HPV16	O
E7	O
peptides	O
were	O
injected	O
into	O
mice	O
.	O
Results	O
show	O
that	O
the	O
tolerizing	O
peptide	O
spread	O
through	O
the	O
body	O
16	O
times	O
faster	O
than	O
the	O
activating	O
peptide	O
and	O
was	O
cleared	O
at	O
least	O
2	O
times	O
faster	O
.	O
The	O
HPV16	O
E7	O
peptide	O
kinetics	O
correlated	O
with	O
the	O
kinetics	O
of	O
HPV16	O
E7	O
-specific	O
CTL	O
induction	O
.	O
In	O
contrast	O
,	O
Ad5	O
E1A	O
peptide	O
injection	O
resulted	O
in	O
physical	O
deletion	O
of	O
preexisting	O
Ad5	O
E1A	O
-specific	O
CTLs	O
within	O
24	O
h	O
after	O
injection	O
.	O
This	O
tolerization	O
occurred	O
at	O
the	O
time	O
when	O
the	O
peptide	O
reached	O
its	O
maximum	O
peptide	O
concentration	O
in	O
the	O
organs	O
.	O
These	O
data	O
suggest	O
that	O
ubiquitous	O
expression	O
of	O
the	O
tolerizing	O
Ad5	O
E1A	O
peptide	O
within	O
a	O
short	O
period	O
of	O
time	O
causes	O
activation-induced	O
cell	O
death	O
of	O
Ad5	O
E1A	O
-specific	O
CTLs	O
.	O
Therefore	O
,	O
information	O
on	O
the	O
pharmacokinetics	O
of	O
peptides	O
is	O
vital	O
for	O
the	O
safety	O
and	O
efficacy	O
of	O
peptide-based	O
vaccines	O
.	O
Smad3	O
and	O
Smad4	B-protein
mediate	I-protein
transforming	I-protein
growth	I-protein
factor-beta1	I-protein
-induced	O
IgA	O
expression	O
in	O
murine	O
B	O
lymphocytes	O
.	O
Transforming	B-protein
growth	I-protein
factor	I-protein
(	O
TGF	O
)	O
-beta1	O
is	O
well	O
established	O
as	O
a	O
critical	O
IgA	O
isotype	O
switching	O
factor	O
and	O
Smad	B-protein
molecules	I-protein
have	O
been	O
reported	O
to	O
act	O
as	O
transducers	O
and	O
transcriptional	B-protein
factors	I-protein
in	O
the	O
expression	O
of	O
TGF-beta1	B-protein
-targeted	O
genes	O
.	O
We	O
examined	O
the	O
involvement	O
of	O
Smad	B-protein
proteins	I-protein
in	O
TGF-beta1	B-protein
-induced	O
IgA	O
expression	O
.	O
First	O
,	O
we	O
found	O
that	O
TGF-beta1	B-protein
significantly	O
increases	O
endogenous	O
germ-line	O
(	O
GL	O
)	O
alpha	O
transcripts	O
by	O
LPS-stimulated	O
CH12.LX.4933	O
(	O
mu	O
(	O
+	O
)	O
)	O
B	O
lymphoma	O
cells	O
.	O
To	O
investigate	O
its	O
signaling	O
mechanisms	O
,	O
the	O
lymphoma	O
cell	O
line	O
was	O
transfected	O
with	O
pFL3	O
that	O
contains	O
the	O
TGF-beta-responsive	O
element	O
of	O
the	O
GLalpha	O
promoter	O
,	O
and	O
stimulated	O
with	O
TGF-beta1	B-protein
.	O
Similar	O
to	O
endogenous	O
GLalpha	O
transcripts	O
,	O
TGF-beta1	B-protein
induces	O
GLalpha	O
promoter	O
activity	O
and	O
overexpression	O
of	O
Smad3	O
markedly	O
enhances	O
the	O
promoter	O
activity	O
.	O
This	O
activity	O
is	O
further	O
augmented	O
by	O
cotransfected	O
Smad4	O
.	O
On	O
the	O
other	O
hand	O
,	O
Smad7	O
substantially	O
abrogates	O
the	O
synergistic	O
effect	O
of	O
Smad3/4	O
on	O
GLalpha	O
promoter	O
activity	O
.	O
In	O
addition	O
,	O
overexpression	O
of	O
Smad3/4	O
enhances	O
TGF-beta1	B-protein
-induced	O
endogenous	O
GLalpha	O
transcripts	O
in	O
normal	O
spleen	O
B	O
cell	O
s	O
.	O
Finally	O
,	O
in	O
the	O
presence	O
of	O
TGF-beta1	B-protein
,	O
overexpression	O
of	O
Smad3/4	O
selectively	O
increases	O
both	O
surface	O
IgA	O
expression	O
and	O
IgA	O
production	O
.	O
The	O
results	O
from	O
the	O
present	O
study	O
indicate	O
that	O
Smad3	O
,	O
Smad4	B-protein
,	O
and	O
Smad7	O
,	O
at	O
least	O
in	O
part	O
,	O
serve	O
as	O
mediators	O
linking	O
TGF-beta1	B-protein
to	O
transcriptional	O
regulation	O
of	O
IgA	O
switching	O
related	O
gene	O
and	O
regulation	O
of	O
IgA	O
class	O
switching	O
.	O
The	O
translesion	O
DNA	O
polymerase	O
zeta	O
plays	O
a	O
major	O
role	O
in	O
Ig	O
and	O
bcl-6	O
somatic	O
hypermutation	O
.	O
Ig	O
somatic	O
mutations	O
would	O
be	O
introduced	O
by	O
a	O
polymerase	O
(	O
pol	O
)	O
while	O
repairing	O
DNA	O
outside	O
main	O
DNA	O
replication	O
.	O
We	O
show	O
that	O
human	O
B	O
cells	O
constitutively	O
express	O
the	O
translesion	O
pol	O
zeta	O
,	O
which	O
effectively	O
extends	O
DNA	O
past	O
mismatched	O
bases	O
(	O
mispair	O
extender	O
)	O
,	O
and	O
pol	O
eta	O
,	O
which	O
bypasses	O
DNA	O
lesions	O
in	O
an	O
error-free	O
fashion	O
.	O
Upon	O
B	O
cell	O
receptor	O
(	O
BCR	B-protein
)	O
engagement	O
and	O
coculture	O
with	O
activated	O
CD4+	O
T	O
cells	O
,	O
these	O
lymphocytes	O
upregulated	O
pol	O
zeta	O
,	O
downregulated	O
pol	O
eta	O
,	O
and	O
mutated	O
the	O
Ig	O
and	O
bcl-6	O
genes	O
.	O
Inhibition	O
of	O
the	O
pol	B-protein
zeta	I-protein
REV3	I-protein
catalytic	I-protein
subunit	I-protein
by	O
specific	O
phosphorothioate-modified	O
oligonucleotides	O
impaired	O
Ig	O
and	O
bcl-6	O
hypermutation	O
and	O
UV	O
damage-induced	O
DNA	O
mutagenesis	O
,	O
without	O
affecting	O
cell	O
cycle	O
or	O
viability	O
.	O
Thus	O
,	O
pol	O
zeta	O
plays	O
a	O
critical	O
role	O
in	O
Ig	O
and	O
bcl-6	O
hypermutation	O
,	O
perhaps	O
facilitated	O
by	O
the	O
downregulation	O
of	O
pol	O
eta	O
.	O
Molecular	O
mechanism	O
of	O
cell	O
cycle	O
progression	O
induced	O
by	O
the	O
oncogene	B-protein
product	I-protein
Tax	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
.	O
The	O
trans-activator	B-protein
protein	I-protein
Tax	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
plays	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
adult	O
T-cell	O
leukemia	O
through	O
,	O
at	O
least	O
in	O
part	O
,	O
its	O
ability	O
to	O
stimulate	O
cell	O
growth	O
.	O
We	O
previously	O
reported	O
that	O
Tax	B-protein
induced	O
cell	O
cycle	O
progression	O
from	O
G0/G1	O
phase	O
to	O
S	O
and	O
G2/M	O
phases	O
in	O
human	O
T-cell	O
line	O
Kit	O
225	O
cells	O
.	O
To	O
elucidate	O
molecular	O
mechanism	O
of	O
Tax	B-protein
-induced	O
cell	O
cycle	O
progression	O
,	O
we	O
systematically	O
examined	O
the	O
effects	O
of	O
Tax	B-protein
on	O
biochemical	O
events	O
associated	O
with	O
cell	O
cycle	O
progression	O
.	O
Introduction	O
of	O
Tax	B-protein
into	O
resting	O
Kit	O
225	O
cells	O
induced	O
activation	O
of	O
the	O
G1/S	O
transition	O
regulation	O
cascade	O
consisting	O
of	O
activation	O
of	O
cyclin	B-protein
dependent	I-protein
kinase	I-protein
2	I-protein
(	O
CDK2	O
)	O
and	O
CDK4	O
,	O
phosphorylation	O
of	O
the	O
Rb	B-protein
family	I-protein
proteins	I-protein
and	O
an	O
increase	O
in	O
free	O
E2F	O
.	O
The	O
kinase	O
activation	O
was	O
found	O
to	O
result	O
from	O
Tax	B-protein
-induced	O
expression	O
of	O
genes	O
for	O
cell	O
cycle	O
regulatory	O
molecules	O
including	O
cyclin	O
D2	O
,	O
cyclin	O
E	O
,	O
E2F1	O
,	O
CDK2	O
,	O
CDK4	O
and	O
CDK6	O
,	O
and	O
Tax	B-protein
-induced	O
reduction	O
of	O
CDK	O
inhibitors	O
p19	O
(	O
INK4d	O
)	O
and	O
p27	O
(	O
Kip1	O
)	O
.	O
These	O
modulations	O
by	O
Tax	B-protein
always	O
paralleled	O
the	O
ability	O
of	O
Tax	B-protein
to	O
activate	O
the	O
NF-kappaB	B-protein
transcription	O
pathway	O
.	O
These	O
results	O
indicate	O
the	O
important	O
role	O
of	O
Tax	B-protein
-mediated	O
trans-activation	O
of	O
the	O
genes	O
for	O
cell	O
cycle	O
regulatory	O
molecules	O
in	O
Tax	B-protein
-induced	O
cell	O
cycle	O
progression	O
.	O
Cot	O
kinase	O
induces	O
cyclooxygenase-2	O
expression	O
in	O
T	O
cells	O
through	O
activation	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	O
activated	O
T	O
cells	O
.	O
Cyclooxygenase-2	O
(	O
COX-2	O
)	O
is	O
induced	O
in	O
human	O
T	O
lymphocytes	O
upon	O
T	O
cell	O
receptor	O
triggering	O
.	O
Here	O
we	O
report	O
that	O
Cot	B-protein
kinase	I-protein
,	O
a	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
kinase	I-protein
kinase	I-protein
involved	O
in	O
T	O
cell	O
activation	O
,	O
up-regulates	O
COX-2	O
gene	O
expression	O
in	O
Jurkat	O
T	O
cells	O
.	O
Induction	O
of	O
COX-2	O
promoter	O
activity	O
by	O
Cot	B-protein
kinase	I-protein
occurred	O
mainly	O
through	O
activation	O
of	O
the	O
nuclear	B-protein
factor	I-protein
of	O
activated	O
T	O
cells	O
(	O
NFAT	B-protein
)	O
.	O
Mutation	O
of	O
the	O
distal	O
(	O
-105/-97	O
)	O
and	O
proximal	O
(	O
-76/-61	O
)	O
NFAT	O
response	O
elements	O
in	O
the	O
COX-2	O
promoter	O
abolished	O
the	O
activation	O
induced	O
by	O
Cot	B-protein
kinase	I-protein
.	O
Even	O
more	O
,	O
coexpression	O
of	O
a	O
dominant	O
negative	O
version	O
of	O
NFAT	B-protein
inhibited	O
Cot	B-protein
kinase	I-protein
-mediated	O
COX-2	O
promoter	O
activation	O
,	O
whereas	O
cotransfection	O
of	O
a	O
constitutively	O
active	O
version	O
of	O
the	O
calcium-dependent	O
phosphatase	O
calcineurin	O
synergizes	O
with	O
Cot	B-protein
kinase	I-protein
in	O
the	O
up-regulation	O
of	O
COX-2	O
promoter	O
-driven	O
transcription	O
.	O
Strikingly	O
,	O
Cot	B-protein
kinase	I-protein
increased	O
transactivation	O
mediated	O
by	O
a	O
GAL4-NFAT	B-protein
fusion	I-protein
protein	I-protein
containing	O
the	O
N-terminal	B-protein
transactivation	I-protein
domain	I-protein
of	O
NFATp	B-protein
.	O
In	O
contrast	O
to	O
phorbol	O
ester	O
plus	O
calcium	O
ionophore	O
A23187	O
,	O
Cot	B-protein
kinase	I-protein
increases	O
both	O
COX-2	O
promoter	O
activity	O
and	O
NFAT	B-protein
-mediated	O
transactivation	O
in	O
a	O
cyclosporin	O
A-independent	O
manner	O
.	O
These	O
data	O
indicate	O
that	O
Cot	O
kinase	O
up-regulates	O
COX-2	O
promoter	O
-driven	O
transcription	O
through	O
the	O
NFAT	O
response	O
elements	O
,	O
being	O
the	O
Cot	B-protein
kinase	I-protein
-induced	O
NFAT	B-protein
-dependent	O
transactivation	O
presumably	O
implicated	O
in	O
this	O
up-regulation	O
.	O
Positive	O
and	O
negative	O
roles	O
of	O
the	O
trans-acting	B-protein
T	I-protein
cell	I-protein
factor-1	I-protein
for	O
the	O
acquisition	O
of	O
distinct	O
Ly-49	B-protein
MHC	I-protein
class	I-protein
I	I-protein
receptors	I-protein
by	O
NK	O
cells	O
.	O
Members	O
of	O
the	O
Ly-49	O
gene	O
family	O
code	O
for	O
class	B-protein
I	I-protein
MHC-specific	I-protein
receptors	I-protein
that	O
regulate	O
NK	O
cell	O
function	O
.	O
Due	O
to	O
a	O
combinatorial	O
distribution	O
of	O
Ly-49	B-protein
receptors	I-protein
,	O
NK	O
cells	O
display	O
considerable	O
clonal	O
heterogeneity	O
.	O
The	O
acquisition	O
of	O
one	O
Ly-49	B-protein
receptor	I-protein
,	O
Ly-49A	O
is	O
strictly	O
dependent	O
on	O
the	O
transcriptional	B-protein
trans-acting	I-protein
factor	I-protein
T	I-protein
cell-specific	I-protein
factor-1	I-protein
(	O
TCF-1	B-protein
)	O
.	O
Indeed	O
,	O
TCF-1	B-protein
binds	O
to	O
two	O
sites	O
in	O
the	O
Ly-49a	O
promoter	O
and	O
regulates	O
its	O
activity	O
,	O
suggesting	O
that	O
the	O
Ly-49a	O
gene	O
is	O
a	O
direct	O
TCF-1	O
target	O
.	O
TCF-1	O
deficiency	O
resulted	O
in	O
the	O
altered	O
usage	O
of	O
additional	O
Ly-49	O
receptors	O
.	O
We	O
show	O
in	O
this	O
study	O
,	O
using	O
TCF-1	B-protein
beta	I-protein
(	I-protein
2	I-protein
)	O
-microglobulin	O
double-deficient	O
mice	O
,	O
that	O
these	O
repertoire	O
alterations	O
are	O
not	O
due	O
to	O
Ly-49/MHC	O
class	O
I	O
interactions	O
.	O
Our	O
findings	O
rather	O
suggest	O
a	O
TCF-1	B-protein
-dependent	O
,	O
cell	O
autonomous	O
effect	O
on	O
the	O
acquisition	O
of	O
multiple	B-protein
Ly-49	I-protein
receptors	I-protein
.	O
Besides	O
reduced	O
receptor	O
usage	O
(	O
Ly-49A	O
and	O
D	O
)	O
,	O
we	O
also	O
observed	O
no	O
effect	O
(	O
Ly-49C	O
)	O
and	O
significantly	O
expanded	O
(	O
Ly-49G	B-protein
and	I-protein
I	I-protein
)	I-protein
receptor	I-protein
usage	O
in	O
the	O
absence	O
of	O
TCF-1	B-protein
.	O
These	O
effects	O
did	O
not	O
in	O
all	O
cases	O
correlate	O
with	O
the	O
presence	O
of	O
TCF	O
binding	O
sites	O
in	O
the	O
respective	O
proximal	O
promoter	O
.	O
Therefore	O
,	O
besides	O
TCF-1	B-protein
binding	O
to	O
the	O
proximal	O
promoter	O
,	O
Ly-49	O
acquisition	O
may	O
also	O
be	O
regulated	O
by	O
TCF-1	B-protein
binding	O
to	O
more	O
distant	O
cis-acting	O
elements	O
and/or	O
by	O
regulating	O
the	O
expression	O
of	O
additional	O
trans-acting	B-protein
factors	I-protein
.	O
Consistent	O
with	O
the	O
observed	O
differential	O
,	O
positive	O
or	O
negative	O
role	O
of	O
TCF-1	B-protein
for	O
Ly-49	O
receptor	O
acquisition	O
,	O
reporter	O
gene	O
assays	O
revealed	O
the	O
presence	O
of	O
an	O
inducing	O
as	O
well	O
as	O
a	O
repressing	O
TCF	O
site	O
in	O
certain	O
proximal	O
Ly-49	O
promoters	O
.	O
These	O
findings	O
reveal	O
an	O
important	O
role	O
of	O
TCF-1	B-protein
for	O
the	O
formation	O
of	O
the	O
NK	O
cell	O
receptor	O
repertoire	O
.	O
Ligation	O
of	O
CD11b	B-protein
and	I-protein
CD11c	I-protein
beta	I-protein
(	I-protein
2	I-protein
)	I-protein
integrins	I-protein
by	I-protein
antibodies	I-protein
or	O
soluble	O
CD23	O
induces	O
macrophage	O
inflammatory	O
protein	O
1alpha	O
(	O
MIP-1alpha	B-protein
)	O
and	O
MIP-1beta	O
production	O
in	O
primary	O
human	O
monocytes	O
through	O
a	O
pathway	O
dependent	O
on	O
nuclear	B-protein
factor-kappaB	I-protein
.	O
Chemokines	B-protein
and	I-protein
adhesion	I-protein
molecules	I-protein
such	O
as	O
integrins	O
play	O
a	O
major	O
part	O
in	O
the	O
trafficking	O
,	O
extravasation	O
,	O
and	O
recruitment	O
of	O
leukocytes	O
to	O
inflammatory	O
sites	O
.	O
This	O
study	O
investigated	O
the	O
effects	O
of	O
beta	O
(	O
2	O
)	O
integrin	O
engagement	O
on	O
chemokine	B-protein
production	O
by	O
freshly	O
isolated	O
human	O
monocytes	O
.	O
We	O
found	O
that	O
ligation	O
of	O
CD11b	B-protein
or	O
CD11c	O
but	O
not	O
CD11a	B-protein
alpha	I-protein
chains	I-protein
of	I-protein
beta	I-protein
(	I-protein
2	I-protein
)	I-protein
integrins	I-protein
by	I-protein
antibodies	I-protein
or	O
soluble	O
CD23	O
(	O
sCD23	O
)	O
fusion	B-protein
proteins	I-protein
rapidly	O
induced	O
transcription	O
and	O
secretion	O
of	O
interleukin	B-protein
8	I-protein
,	O
macrophage	O
inflammatory	O
protein	O
(	O
MIP	O
)	O
1alpha	O
,	O
and	O
MIP-1beta	B-protein
.	O
Because	O
the	O
promoters	O
of	O
these	O
chemokine	O
genes	O
contain	O
kappaB	O
binding	O
sites	O
,	O
we	O
assessed	O
the	O
possible	O
role	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
in	O
controlling	O
induction	O
of	O
the	O
genes	O
through	O
beta	O
(	O
2	O
)	O
integrin	O
engagement	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
sCD23	O
or	O
antibodies	B-protein
to	O
CD11b	B-protein
or	O
to	O
CD11c	O
up-regulated	O
DNA-binding	O
activity	O
of	O
NF-kappaB	B-protein
.	O
Activation	O
of	O
NF-kappaB	B-protein
was	O
accompanied	O
by	O
degradation	O
of	O
its	O
cytosolic	O
inhibitor	O
IkappaB-alpha	B-protein
.	O
Blockade	O
of	O
depletion	O
of	O
IkappaB-alpha	B-protein
by	O
proteasome	O
inhibitors	O
(	O
proteasome	B-protein
inhibitor	I-protein
I	I-protein
or	O
acetyl-leucinyl-leucinyl-norleucinal	O
)	O
led	O
to	O
concomitant	O
inhibition	O
of	O
NF-kappaB	B-protein
DNA-binding	O
activity	O
and	O
expression	O
of	O
MIP-1alpha	B-protein
and	O
MIP-1beta	O
messenger	O
RNA	O
induced	O
by	O
beta	O
(	O
2	O
)	O
integrin	O
ligation	O
.	O
These	O
results	O
suggest	O
that	O
triggering	O
of	O
CD11b	B-protein
or	I-protein
CD11c	I-protein
beta	I-protein
(	I-protein
2	I-protein
)	I-protein
integrin	I-protein
on	O
primary	O
human	O
monocytes	O
provides	O
activation	O
signals	O
leading	O
to	O
nuclear	O
translocation	O
of	O
NF-kappaB	B-protein
and	O
subsequent	O
secretion	O
of	O
MIP-1alpha	B-protein
and	O
MIP-1beta	B-protein
that	O
may	O
have	O
an	O
important	O
role	O
in	O
recruitment	O
of	O
other	O
inflammatory	O
cells	O
during	O
initiation	O
of	O
an	O
inflammatory	O
response	O
Synergistic	O
transcriptional	O
activation	O
of	O
human	O
Acyl-coenzyme	O
A	O
:	O
cholesterol	O
acyltransterase-1	O
gene	O
by	O
interferon-gamma	B-protein
and	O
all-trans-retinoic	O
acid	O
THP-1	O
cells	O
.	O
Acyl-coenzyme	O
A	O
:	O
cholesterol	O
acyltransferase	O
(	O
ACAT	O
)	O
is	O
an	O
intracellular	B-protein
enzyme	I-protein
involved	O
in	O
cellular	O
cholesterol	O
homeostasis	O
and	O
in	O
atherosclerotic	O
foam	O
cell	O
formation	O
.	O
Human	O
ACAT-1	O
gene	O
contains	O
two	O
promoters	O
(	O
P1	O
and	O
P7	O
)	O
,	O
each	O
located	O
in	O
a	O
different	O
chromosome	O
(	O
1	O
and	O
7	O
)	O
(	O
Li	O
,	O
B.	O
L.	O
,	O
Li	O
,	O
X.	O
L.	O
,	O
Duan	O
,	O
Z.	O
J.	O
,	O
Lee	O
,	O
O.	O
,	O
Lin	O
,	O
S.	O
,	O
Ma	O
,	O
Z.	O
M.	O
,	O
Chang	O
,	O
C.	O
C.	O
,	O
Yang	O
,	O
X.	O
Y.	O
,	O
Park	O
,	O
J.	O
P.	O
,	O
Mohandas	O
,	O
T.	O
K.	O
,	O
Noll	O
,	O
W.	O
,	O
Chan	O
,	O
L.	O
,	O
and	O
Chang	O
,	O
T.	O
Y.	O
(	O
1999	O
)	O
J.	O
Biol	O
274	O
,	O
11060-11071	O
)	O
.	O
Interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
,	O
a	O
cytokine	B-protein
that	O
exerts	O
many	O
pro-atherosclerotic	O
effects	O
in	O
vivo	O
,	O
causes	O
up-regulation	O
of	O
ACAT-1	O
mRNA	O
in	O
human	O
blood	O
monocyte-derived	O
macrophages	O
and	O
macrophage-like	O
cells	O
but	O
not	O
in	O
other	O
cell	O
types	O
.	O
To	O
examine	O
the	O
molecular	O
nature	O
of	O
this	O
observation	O
,	O
we	O
identified	O
within	O
the	O
ACAT-1	O
P1	O
promoter	O
a	O
159-base	O
pair	O
core	O
region	O
.	O
This	O
region	O
contains	O
4	O
Sp1	O
elements	O
and	O
an	O
IFN-gamma	B-protein
activated	O
sequence	O
(	O
GAS	O
)	O
that	O
overlaps	O
with	O
the	O
second	O
Sp1	O
element	O
.	O
In	O
the	O
monocytic	O
cell	O
line	O
THP-1	O
cell	O
,	O
the	O
combination	O
of	O
IFN-gamma	B-protein
and	O
all-trans-retinoic	O
acid	O
(	O
a	O
known	O
differentiation	O
agent	O
)	O
enhances	O
the	O
ACAT-1	O
P1	O
promoter	O
but	O
not	O
the	O
P7	O
promoter	O
.	O
Additional	O
experiments	O
showed	O
that	O
all-trans-retinoic	O
acid	O
causes	O
large	O
induction	O
of	O
the	O
transcription	B-protein
factor	I-protein
STAT1	I-protein
,	O
while	O
IFN-gamma	O
causes	O
activation	O
of	O
STAT1	B-protein
such	O
that	O
it	O
binds	O
to	O
the	O
GAS/Sp1	O
site	O
in	O
the	O
ACAT-1	O
P1	O
promoter	O
.	O
Our	O
work	O
provides	O
a	O
molecular	O
mechanism	O
to	O
account	O
for	O
the	O
effect	O
of	O
IFN-gamma	B-protein
in	O
causing	O
transcriptional	O
activation	O
of	O
ACAT-1	O
in	O
macrophage-like	O
cells	O
.	O
Inhaled	O
nitric	O
oxide	O
down-regulates	O
intrapulmonary	O
nitric	O
oxide	O
production	O
in	O
lipopolysaccharide-induced	O
acute	O
lung	O
injury	O
.	O
OBJECTIVE	O
:	O
To	O
examine	O
whether	O
inhaled	O
nitric	O
oxide	O
(	O
NO	O
)	O
affected	O
the	O
intrapulmonary	O
production	O
of	O
NO	O
,	O
reactive	O
oxygen	O
species	O
,	O
and	O
nuclear	B-protein
factor-kappaB	I-protein
in	O
a	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
model	O
of	O
acute	O
lung	O
injury	O
.	O
DESIGN	O
:	O
Prospective	O
,	O
randomized	O
,	O
laboratory	O
study	O
.	O
SETTING	O
:	O
Experimental	O
laboratory	O
at	O
a	O
biomedical	O
institute	O
.	O
SUBJECTS	O
:	O
Twenty	O
male	O
rabbits	O
weighing	O
2.5-3.5	O
kg	O
.	O
INTERVENTIONS	O
:	O
Saline	O
or	O
LPS	O
(	O
5	O
mg/kg	O
of	O
body	O
weight	O
)	O
was	O
administered	O
intravenously	O
with	O
or	O
without	O
NO	O
inhalation	O
(	O
10	O
ppm	O
)	O
in	O
each	O
group	O
of	O
five	O
rabbits	O
.	O
MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
LPS	O
increased	O
the	O
lung	O
leak	O
index	O
,	O
the	O
neutrophils	O
and	O
NO	O
levels	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
,	O
and	O
NO	O
levels	O
produced	O
by	O
resting	O
and	O
stimulated	O
alveolar	O
macrophages	O
.	O
Inhaled	O
NO	O
decreased	O
the	O
lung	O
leak	O
index	O
,	O
the	O
neutrophils	O
and	O
NO	O
levels	O
as	O
measured	O
by	O
nitrite	O
levels	O
in	O
the	O
lavage	O
fluid	O
,	O
and	O
NO	O
produced	O
by	O
the	O
resting	O
and	O
stimulated	O
alveolar	O
macrophages	O
.	O
Inhaled	O
NO	O
also	O
blocked	O
the	O
activities	O
of	O
reactive	O
oxygen	O
species	O
and	O
nuclear	B-protein
factor-kappaB	I-protein
binding	O
to	O
DNA	O
in	O
lavage	O
cells	O
and	O
in	O
alveolar	O
macrophages	O
.	O
CONCLUSION	O
:	O
Inhaled	O
NO	O
attenuates	O
LPS-induced	O
acute	O
lung	O
injury	O
,	O
possibly	O
by	O
decreasing	O
NO	O
production	O
in	O
the	O
lungs	O
.	O
The	O
mechanism	O
of	O
reducing	O
NO	O
production	O
resulting	O
from	O
inhaled	O
NO	O
may	O
involve	O
,	O
in	O
part	O
,	O
the	O
activities	O
of	O
reactive	O
oxygen	O
species	O
and/or	O
nuclear	B-protein
factor-kappaB	I-protein
.	O
Treatment	O
of	O
allergic	O
airway	O
inflammation	O
and	O
hyperresponsiveness	O
by	O
antisense-induced	O
local	O
blockade	O
of	O
GATA-3	B-protein
expression	O
.	O
Recent	O
studies	O
in	O
transgenic	O
mice	O
have	O
revealed	O
that	O
expression	O
of	O
a	O
dominant	O
negative	O
form	O
of	O
the	O
transcription	B-protein
factor	I-protein
GATA-3	I-protein
in	O
T	O
cells	O
can	O
prevent	O
T	O
helper	O
cell	O
type	O
2	O
(	O
Th2	O
)	O
-mediated	O
allergic	O
airway	O
inflammation	O
in	O
mice	O
.	O
However	O
,	O
it	O
remains	O
unclear	O
whether	O
GATA-3	B-protein
plays	O
a	O
role	O
in	O
the	O
effector	O
phase	O
of	O
allergic	O
airway	O
inflammation	O
and	O
whether	O
antagonizing	O
the	O
expression	O
and/or	O
function	O
of	O
GATA-3	B-protein
can	O
be	O
used	O
for	O
the	O
therapy	O
of	O
allergic	O
airway	O
inflammation	O
and	O
hyperresponsiveness	O
.	O
Here	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
locally	O
antagonizing	O
GATA-3	O
function	O
in	O
a	O
murine	O
model	O
of	O
asthma	O
.	O
We	O
could	O
suppress	O
GATA-3	O
expression	O
in	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-4	I-protein
-producing	I-protein
T	I-protein
cells	I-protein
in	O
vitro	O
and	O
in	O
vivo	O
by	O
an	O
antisense	O
phosphorothioate	O
oligonucleotide	O
overlapping	O
the	O
translation	O
start	O
site	O
of	O
GATA-3	B-protein
,	O
whereas	O
nonsense	O
control	O
oligonucleotides	O
were	O
virtually	O
inactive	O
.	O
In	O
a	O
murine	O
model	O
of	O
asthma	O
associated	O
with	O
allergic	O
pulmonary	O
inflammation	O
and	O
hyperresponsiveness	O
in	O
ovalbumin	O
(	O
OVA	O
)	O
-sensitized	O
mice	O
,	O
local	O
intranasal	O
administration	O
of	O
fluorescein	O
isothiocyanate-labeled	O
GATA-3	O
antisense	O
oligonucleotides	O
led	O
to	O
DNA	O
uptake	O
in	O
lung	O
cells	O
associated	O
with	O
a	O
reduction	O
of	O
intracellular	O
GATA-3	B-protein
expression	O
.	O
Such	O
intrapulmonary	O
blockade	O
of	O
GATA-3	B-protein
expression	O
caused	O
an	O
abrogation	O
of	O
signs	O
of	O
lung	O
inflammation	O
including	O
infiltration	O
of	O
eosinophils	O
and	O
Th2	B-protein
cytokine	I-protein
production	O
.	O
Furthermore	O
,	O
treatment	O
with	O
antisense	O
but	O
not	O
nonsense	O
oligonucleotides	O
induced	O
a	O
significant	O
reduction	O
of	O
airway	O
hyperresponsiveness	O
in	O
OVA-sensitized	O
mice	O
to	O
levels	O
comparable	O
to	O
saline-treated	O
control	O
mice	O
,	O
as	O
assessed	O
by	O
both	O
enhanced	O
pause	O
(	O
PenH	O
)	O
responses	O
and	O
pulmonary	O
resistance	O
determined	O
by	O
body	O
plethysmography	O
.	O
These	O
data	O
indicate	O
a	O
critical	O
role	O
for	O
GATA-3	B-protein
in	O
the	O
effector	O
phase	O
of	O
a	O
murine	O
asthma	O
model	O
and	O
suggest	O
that	O
local	O
delivery	O
of	O
GATA-3	B-protein
antisense	O
oligonucleotides	O
may	O
be	O
a	O
novel	O
approach	O
for	O
the	O
treatment	O
of	O
airway	O
hyperresponsiveness	O
such	O
as	O
in	O
asthma	O
.	O
This	O
approach	O
has	O
the	O
potential	O
advantage	O
of	O
suppressing	O
the	O
expression	O
of	O
various	O
proinflammatory	O
Th2	O
cytokines	B-protein
simultaneously	O
rather	O
than	O
suppressing	O
the	O
activity	O
of	O
a	O
single	B-protein
cytokine	I-protein
.	O
T	O
helper-cell	O
phenotype	O
regulates	O
atherosclerosis	O
in	O
mice	O
under	O
conditions	O
of	O
mild	O
hypercholesterolemia	O
.	O
BACKGROUND	O
:	O
T	O
cells	O
are	O
implicated	O
in	O
atherosclerosis	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
genetic	O
control	O
or	O
molecular	O
pathways	O
,	O
especially	O
under	O
conditions	O
of	O
mild	O
hypercholesterolemia	O
.	O
METHODS	O
AND	O
RESULTS	O
:	O
BALB/c	O
mice	O
,	O
making	O
a	O
CD4+	O
Th2	O
(	O
IL-4+	O
)	O
cell	O
response	O
,	O
express	O
both	O
MHC	B-protein
class	I-protein
II	I-protein
antigens	I-protein
(	O
IA	O
(	O
d	O
)	O
,	O
IE	O
(	O
d	O
)	O
)	O
and	O
are	O
atherosclerosis-resistant	O
.	O
C57Bl/6	O
mice	O
produce	O
a	O
CD4+	O
Th1	O
(	O
interferon	B-protein
[	I-protein
IFN	I-protein
]	I-protein
gamma+	I-protein
)	O
response	O
,	O
express	O
IA	O
(	O
b	O
)	O
but	O
no	O
IE	O
,	O
and	O
are	O
atherosclerosis-prone	O
.	O
To	O
evaluate	O
T	O
helper-cell	O
phenotype	O
in	O
fatty	O
streak	O
formation	O
,	O
wild-type	O
C57Bl/6	O
mice	O
(	O
IA	O
(	O
b	O
)	O
+IE-	O
)	O
and	O
transgenic	O
mice	O
,	O
either	O
AB	B-protein
(	O
o	O
)	O
,	O
IA	O
(	O
b	O
)	O
-IE-	O
;	O
ABEalpha	O
,	O
IA-IE	O
(	O
k	O
)	O
+	O
;	O
or	O
BL	O
:	O
TG	O
:	O
Ealpha	O
,	O
IA	O
(	O
b	O
)	O
+IE	O
(	O
k	O
)	O
+	O
,	O
were	O
fed	O
a	O
high-cholesterol	O
diet	O
for	O
16	O
weeks	O
and	O
evaluated	O
histomorphometrically	O
for	O
aortic	O
lesions	O
.	O
Lesion	O
size	O
in	O
AB	O
(	O
o	O
)	O
,	O
ABEalpha	O
,	O
and	O
BL	O
:	O
TG	O
:	O
Ealpha	O
strains	O
was	O
decreased	O
by	O
54	O
%	O
,	O
79	O
%	O
,	O
and	O
82	O
%	O
,	O
respectively	O
,	O
compared	O
with	O
wild-type	O
,	O
correlating	O
with	O
decreased	O
Th1	O
and	O
increased	O
Th2	O
expression	O
and	O
suggesting	O
that	O
T	O
helper-cell	O
phenotype	O
is	O
important	O
in	O
fatty	O
lesion	O
development	O
.	O
Decreasing	O
Th1	O
cells	O
by	O
antibodies	O
(	O
alpha-CD4	O
)	O
or	O
cytokines	B-protein
(	O
IL-4	B-protein
)	O
also	O
caused	O
>	O
/=80	O
%	O
reductions	O
in	O
lesion	O
size	O
.	O
Immunohistology	O
revealed	O
IFN-gamma	B-protein
,	O
but	O
not	O
IL-4	B-protein
,	O
colocalized	O
with	O
activated	O
macrophages	O
.	O
Confirming	O
these	O
findings	O
in	O
a	O
different	O
mouse	O
strain	O
,	O
BALB/c	O
Stat	O
6	O
knockout	O
mice	O
(	O
Th2	O
cell-deficient	O
)	O
developed	O
aortic	O
lesions	O
comparable	O
to	O
C57Bl/6	O
mice	O
on	O
the	O
same	O
diet	O
.	O
CONCLUSIONS	O
:	O
In	O
mildly	O
hypercholesterolemic	O
C57Bl/6	O
mice	O
,	O
presence	O
of	O
IA	O
(	O
b	O
)	O
and	O
absence	O
of	O
IE	O
regulated	O
CD4+	O
T	O
helper-cell	O
phenotype	O
;	O
fatty	O
lesions	O
were	O
proportional	O
to	O
IFNgamma+	O
Th1	O
cells	O
in	O
both	O
C57Bl/6	O
and	O
BALB/c	O
strains	O
.	O
IFN-gamma	B-protein
may	O
participate	O
through	O
macrophage	O
activation	O
,	O
whereas	O
IL-4	B-protein
may	O
act	O
to	O
limit	O
Th1-cell	O
response	O
.	O
Requirement	O
for	O
p38	B-protein
and	I-protein
p44/p42	I-protein
mitogen-activated	I-protein
protein	I-protein
kinases	I-protein
in	O
RAGE	B-protein
-mediated	O
nuclear	B-protein
factor-kappaB	I-protein
transcriptional	I-protein
activation	I-protein
and	I-protein
cytokine	I-protein
secretion	I-protein
.	I-protein
Advanced	I-protein
glycation	I-protein
end	I-protein
product	I-protein
(	O
AGE	O
)	O
activation	O
of	O
the	O
signal-transducing	B-protein
receptor	I-protein
for	O
AGE	O
(	O
RAGE	B-protein
)	O
has	O
been	O
linked	O
to	O
a	O
proinflammatory	O
phenotypic	O
change	O
within	O
cells	O
.	O
However	O
,	O
the	O
precise	O
intracellular	O
signaling	O
pathways	O
involved	O
have	O
not	O
been	O
elucidated	O
.	O
We	O
demonstrate	O
here	O
that	O
human	B-protein
serum	I-protein
albumin	I-protein
modified	O
with	O
N	O
(	O
varepsilon	O
)	O
-	O
(	O
carboxymethyl	O
)	O
lysine	O
(	O
CML	O
)	O
,	O
a	O
major	O
AGE	O
adduct	O
that	O
progressively	O
accumulates	O
with	O
aging	O
,	O
diabetes	O
,	O
and	O
renal	O
failure	O
,	O
induced	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappaB	O
-driven	O
reporter	O
gene	O
expression	O
in	O
human	O
monocytic	O
THP-1	O
cells	O
.	O
The	O
NF-kappaB	O
response	O
was	O
blocked	O
with	O
a	O
synthetic	O
peptide	O
corresponding	O
to	O
the	O
putative	B-protein
ligand-binding	I-protein
domain	I-protein
of	O
RAGE	B-protein
,	O
with	O
anti-	O
RAGE	O
antiserum	O
,	O
and	O
by	O
coexpression	O
of	O
truncated	B-protein
receptors	I-protein
lacking	O
the	O
intracellular	B-protein
domain	I-protein
.	O
Signal	O
transduction	O
from	O
RAGE	O
to	O
NF-kappaB	B-protein
involved	O
the	O
generation	O
of	O
reactive	O
oxygen	O
species	O
,	O
since	O
reporter	O
gene	O
expression	O
was	O
blocked	O
with	O
the	O
antioxidant	O
N-acetyl-L-cysteine	O
.	O
CML-modified	B-protein
albumin	I-protein
produced	O
rapid	O
transient	O
activation	O
of	O
tyrosine	O
phosphorylation	O
,	O
extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
1	I-protein
and	I-protein
2	I-protein
,	O
and	O
p38	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
,	O
but	O
not	O
c-Jun	B-protein
NH	I-protein
(	I-protein
2	I-protein
)	I-protein
-terminal	I-protein
kinase	I-protein
.	O
RAGE	B-protein
-mediated	O
NF-kappaB	O
activation	O
was	O
suppressed	O
by	O
the	O
selective	O
p38	O
MAPK	O
inhibitor	O
SB203580	O
and	O
by	O
coexpression	O
of	O
a	O
kinase-dead	O
p38	B-protein
dominant-negative	I-protein
mutant	I-protein
.	O
Activation	O
of	O
NF-kappaB	B-protein
by	O
CML-modified	B-protein
albumin	I-protein
increased	O
secretion	O
of	O
proinflammatory	B-protein
cytokines	I-protein
(	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
interleukin-1beta	O
,	O
and	O
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
)	O
severalfold	O
,	O
and	O
inhibition	O
of	O
p38	B-protein
MAPK	I-protein
blocked	O
these	O
increases	O
.	O
These	O
results	O
indicate	O
that	O
p38	B-protein
MAPK	I-protein
activation	O
mediates	O
RAGE	B-protein
-induced	O
NF-kappaB	B-protein
-dependent	O
secretion	O
of	O
proinflammatory	B-protein
cytokines	I-protein
and	O
suggest	O
that	O
accelerated	O
inflammation	O
may	O
be	O
a	O
consequence	O
of	O
cellular	O
activation	O
induced	O
by	O
this	O
receptor	O
.	O
Antigen-receptor	O
cross-linking	O
and	O
lipopolysaccharide	O
trigger	O
distinct	O
phosphoinositide	O
3-kinase	B-protein
-dependent	O
pathways	O
to	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
primary	O
B	O
cells	O
.	O
The	O
NF-kappaB/Rel	B-protein
transcription	I-protein
factors	I-protein
play	O
an	O
important	O
role	O
in	O
the	O
expression	O
of	O
genes	O
involved	O
in	O
B	O
cell	O
development	O
,	O
differentiation	O
and	O
function	O
.	O
Nuclear	O
NF-kappaB	B-protein
is	O
induced	O
in	O
B	O
cells	O
by	O
engagement	O
of	O
either	O
the	O
BCR	B-protein
or	O
CD40	B-protein
or	O
by	O
stimulation	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O
Despite	O
the	O
importance	O
of	O
NF-kappaB	B-protein
to	O
B	O
cell	O
function	O
,	O
little	O
is	O
known	O
about	O
the	O
signaling	O
pathways	O
leading	O
to	O
NF-kappaB	B-protein
activation	O
.	O
In	O
this	O
report	O
we	O
address	O
the	O
role	O
of	O
phosphoinositide	O
3'-kinase	O
(	O
PI	B-protein
3-kinase	I-protein
)	O
in	O
BCR	B-protein
-	O
and	O
LPS-induced	O
NF-kappaB	O
activation	O
using	O
populations	O
of	O
primary	O
murine	O
resting	O
B	O
cells	O
.	O
Using	O
the	O
specific	O
pharmacological	O
inhibitors	O
of	O
PI	B-protein
3-kinase	I-protein
,	O
Wortmannin	O
and	O
LY294002	O
,	O
we	O
demonstrate	O
that	O
PI	O
3-kinase	O
activity	O
is	O
vital	O
for	O
BCR	B-protein
-induced	O
NF-kappaB	B-protein
DNA-binding	O
activity	O
.	O
Furthermore	O
,	O
we	O
show	O
that	O
this	O
is	O
achieved	O
via	O
protein	B-protein
kinase	I-protein
C	I-protein
-dependent	O
degradation	O
of	O
IkappaBalpha	B-protein
.	O
Similar	O
analyses	O
reveal	O
that	O
PI	B-protein
3-kinase	I-protein
is	O
also	O
critical	O
in	O
triggering	O
NF-kappaB	O
DNA-binding	O
activity	O
and	O
IkappaBalpha	B-protein
degradation	O
following	O
LPS	O
stimulation	O
.	O
Interestingly	O
,	O
a	O
PKC	O
inhibitor	O
which	O
blocked	O
the	O
BCR	B-protein
-induced	O
IkappaBalpha	O
degradation	O
had	O
no	O
effect	O
on	O
the	O
degradation	O
of	O
IkappaBalpha	B-protein
after	O
LPS	O
stimulation	O
.	O
Taken	O
together	O
,	O
our	O
results	O
indicate	O
the	O
involvement	O
of	O
PI	B-protein
3-kinase	I-protein
in	O
at	O
least	O
two	O
distinct	O
signaling	O
pathways	O
leading	O
to	O
activation	O
of	O
NF-kappaB	B-protein
in	O
B	O
cells	O
.	O
Tetramer-guided	O
epitope	O
mapping	O
:	O
rapid	O
identification	O
and	O
characterization	O
of	O
immunodominant	B-protein
CD4+	I-protein
T	I-protein
cell	I-protein
epitopes	I-protein
from	I-protein
complex	I-protein
antigens	I-protein
.	O
T	O
cell	O
responses	O
to	O
Ags	O
involve	O
recognition	O
of	O
selected	O
peptide	O
epitopes	O
contained	O
within	O
the	O
antigenic	B-protein
protein	I-protein
.	O
In	O
this	O
report	O
,	O
we	O
describe	O
a	O
new	O
approach	O
for	O
direct	O
identification	O
of	O
CD4+	O
T	O
cell	O
epitopes	O
of	O
complex	O
Ags	O
that	O
uses	O
human	O
class	O
II	O
tetramers	O
to	O
identify	O
reactive	O
cells	O
.	O
With	O
a	O
panel	O
of	O
60	O
overlapping	O
peptides	O
covering	O
the	O
entire	O
sequence	O
of	O
the	O
VP16	B-protein
protein	I-protein
,	O
a	O
major	B-protein
Ag	I-protein
for	O
HSV-2	O
,	O
we	O
generated	O
a	O
panel	O
of	O
class	B-protein
II	I-protein
MHC	I-protein
tetramers	I-protein
loaded	O
with	O
peptide	O
pools	O
that	O
were	O
used	O
to	O
stain	O
peripheral	O
lymphocytes	O
of	O
an	O
HSV-2	O
infected	O
individual	O
.	O
With	O
this	O
approach	O
,	O
we	O
identified	O
four	O
new	O
DRA1*0101/DRB1*0401-	O
and	O
two	O
DRA1*0101/DRB1*0404-restricted	O
,	O
VP16-specific	O
epitopes	O
.	O
By	O
using	O
tetramers	O
to	O
sort	O
individual	O
cells	O
,	O
we	O
easily	O
obtained	O
a	O
large	O
number	O
of	O
clones	O
specific	O
to	O
these	O
epitopes	O
.	O
Although	O
DRA1*0101/DRB1*0401	O
and	O
DRA1*0101/DRB1*0404	B-protein
are	O
structurally	O
very	O
similar	O
,	O
nonoverlapping	O
VP16	O
epitopes	O
were	O
identified	O
,	O
illustrating	O
high	O
selectivity	O
of	O
individual	O
allele	O
polymorphisms	O
within	O
common	O
MHC	O
variants	O
.	O
This	O
rapid	O
approach	O
to	O
detecting	O
CD4+	O
T	O
cell	O
epitopes	O
from	O
complex	O
Ags	O
can	O
be	O
applied	O
to	O
any	O
known	O
Ag	O
that	O
gives	O
a	O
T	O
cell	O
response	O
.	O
Localized	O
pancreatic	O
NF-kappaB	O
activation	O
and	O
inflammatory	O
response	O
in	O
taurocholate-induced	O
pancreatitis	O
.	O
Transcription	B-protein
factor	I-protein
nuclear	I-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
is	O
activated	O
in	O
cerulein	O
pancreatitis	O
and	O
mediates	O
cytokine	O
expression	O
.	O
The	O
role	O
of	O
transcription	B-protein
factor	I-protein
activation	O
in	O
other	O
models	O
of	O
pancreatitis	O
has	O
not	O
been	O
established	O
.	O
Here	O
we	O
report	O
upregulation	O
of	O
NF-kappaB	B-protein
and	O
inflammatory	O
molecules	O
,	O
and	O
their	O
correlation	O
with	O
local	O
pancreatic	O
injury	O
,	O
in	O
a	O
model	O
of	O
severe	O
pancreatitis	O
.	O
Rats	O
received	O
intraductal	O
infusion	O
of	O
taurocholate	O
or	O
saline	O
,	O
and	O
the	O
pancreatic	O
head	O
and	O
tail	O
were	O
analyzed	O
separately	O
.	O
NF-kappaB	B-protein
and	O
activator	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
activation	O
were	O
assessed	O
by	O
gel	O
shift	O
assay	O
,	O
and	O
mRNA	O
expression	O
of	O
interleukin-6	B-protein
,	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
KC	O
,	O
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
,	O
and	O
inducible	O
nitric	O
oxide	O
synthase	O
was	O
assessed	O
by	O
semiquantitative	O
RT-PCR	O
.	O
Morphological	O
damage	O
and	O
trypsin	O
activation	O
were	O
much	O
greater	O
in	O
the	O
pancreatic	O
head	O
than	O
tail	O
,	O
in	O
parallel	O
with	O
a	O
stronger	O
activation	O
of	O
NF-kappaB	B-protein
and	O
cytokine	O
mRNA	O
.	O
Saline	O
infusion	O
mildly	O
affected	O
these	O
parameters	O
.	O
AP-1	B-protein
was	O
strongly	O
activated	O
in	O
both	O
pancreatic	O
segments	O
after	O
either	O
taurocholate	O
or	O
saline	O
infusion	O
.	O
NF-kappaB	O
inhibition	O
with	O
N-acetylcysteine	O
ameliorated	O
the	O
local	O
inflammatory	O
response	O
.	O
Correlation	O
between	O
localized	O
NF-kappaB	B-protein
activation	O
,	O
cytokine	O
upregulation	O
,	O
and	O
tissue	O
damage	O
suggests	O
a	O
key	O
role	O
for	O
NF-kappaB	B-protein
in	O
the	O
development	O
of	O
the	O
inflammatory	O
response	O
of	O
acute	O
pancreatitis	O
.	O
CD45	B-protein
tyrosine	I-protein
phosphatase	I-protein
controls	O
common	O
gamma-chain	B-protein
cytokine	I-protein
-mediated	O
STAT	O
and	O
extracellular	O
signal-related	O
kinase	O
phosphorylation	O
in	O
activated	O
human	O
lymphoblasts	O
:	O
inhibition	O
of	O
proliferation	O
without	O
induction	O
of	O
apoptosis	O
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
test	O
whether	O
CD45	B-protein
signals	O
can	O
influence	O
signaling	O
processes	O
in	O
activated	O
human	O
lymphoblasts	O
.	O
To	O
this	O
end	O
,	O
we	O
generated	O
lymphoblasts	O
which	O
proliferate	O
in	O
response	O
to	O
common	O
gamma-chain	B-protein
cytokines	I-protein
,	O
but	O
readily	O
undergo	O
apoptosis	O
after	O
cytokine	O
withdrawal	O
.	O
In	O
experiments	O
with	O
the	O
CD45R0	B-protein
mAb	O
UCHL-1	O
,	O
but	O
not	O
control	O
CD45	O
mAbs	O
,	O
we	O
found	O
significant	O
inhibition	O
of	O
proliferation	O
.	O
Interestingly	O
,	O
the	O
pan-CD45	B-protein
mAb	I-protein
GAP8.3	I-protein
,	O
which	O
is	O
most	O
effective	O
in	O
inhibition	O
of	O
OKT-3-mediated	O
proliferation	O
in	O
quiescent	O
lymphocytes	O
,	O
was	O
ineffective	O
in	O
lymphoblasts	O
.	O
Addition	O
of	O
CD3	B-protein
mAb	I-protein
OKT-3	I-protein
had	O
no	O
influence	O
on	O
IL-2-mediated	O
proliferation	O
(	O
with	O
or	O
without	O
UCHL-1	O
)	O
.	O
In	O
contrast	O
,	O
after	O
addition	O
of	O
OKT-3	O
to	O
IL-4	B-protein
-	O
and	O
IL-7	O
-stimulated	O
proliferation	O
assays	O
,	O
UCHL-1	O
signals	O
could	O
not	O
significantly	O
alter	O
cellular	O
proliferation	O
.	O
We	O
did	O
not	O
find	O
induction	O
of	O
apoptosis	O
following	O
CD45R0	O
signaling	O
.	O
In	O
Western	O
blots	O
using	O
mAbs	O
detecting	O
phosphorylated	B-protein
STAT-3	I-protein
,	O
STAT-5	O
,	O
STAT-6	B-protein
,	O
or	O
extracellular	B-protein
signal-related	I-protein
kinase	I-protein
1/2	I-protein
,	O
we	O
found	O
that	O
CD45R0	O
signaling	O
could	O
effectively	O
diminish	O
phosphorylation	O
of	O
these	O
intracellular	O
signaling	O
components	O
.	O
Using	O
RT-PCR	O
,	O
we	O
found	O
that	O
CD45R0	O
signaling	O
inhibited	O
IL-2	O
mRNA	O
production	O
without	O
major	O
influence	O
on	O
IL-13	B-protein
,	O
IL-5	B-protein
,	O
or	O
IFN-gamma	O
mRNA	O
levels	O
.	O
Costimulation	O
with	O
OKT-3	O
and	O
IL-2	B-protein
optimally	O
induced	O
secretion	O
of	O
IFN-gamma	B-protein
,	O
TNF-alpha	B-protein
,	O
and	O
IL-5	B-protein
,	O
which	O
was	O
not	O
decreased	O
by	O
CD45	O
signals	O
.	O
In	O
conclusion	O
,	O
we	O
illustrate	O
that	O
CD45R0	O
signals	O
control	O
early	O
cytokine	O
receptor-associated	O
signaling	O
processes	O
and	O
mRNA	O
and	O
DNA	O
synthesis	O
in	O
activated	O
human	O
lymphoblasts	O
.	O
Furthermore	O
,	O
we	O
show	O
the	O
existence	O
of	O
CD45	O
epitopes	O
(	O
GAP8.3	O
)	O
,	O
which	O
are	O
active	O
and	O
critical	O
for	O
signaling	O
in	O
quiescent	O
lymphocytes	O
,	O
but	O
are	O
nonfunctional	O
in	O
activated	O
human	O
lymphoblasts	O
.	O
Pax5	O
determines	O
the	O
identity	O
of	O
B	O
cells	O
from	O
the	O
beginning	O
to	O
the	O
end	O
of	O
B-lymphopoiesis	O
.	O
Despite	O
being	O
one	O
of	O
the	O
most	O
intensively	O
studied	O
cell	O
types	O
,	O
the	O
molecular	O
basis	O
of	O
B	O
cell	O
specification	O
is	O
largely	O
unknown	O
.	O
The	O
Pax5	O
gene	O
encoding	O
the	O
transcription	B-protein
factor	I-protein
BSAP	B-protein
is	O
required	O
for	O
progression	O
of	O
B-lymphopoiesis	O
beyond	O
the	O
pro-B	O
cell	O
stage	O
.	O
Pax5-deficient	O
pro-B	O
cells	O
are	O
,	O
however	O
,	O
not	O
yet	O
committed	O
to	O
the	O
B-lymphoid	O
lineage	O
,	O
but	O
instead	O
have	O
a	O
broad	O
lymphomyeloid	O
developmental	O
potential	O
.	O
Pax5	O
appears	O
to	O
mediate	O
B-lineage	O
commitment	O
by	O
repressing	O
the	O
transcription	O
of	O
non-B-lymphoid	O
genes	O
and	O
by	O
simultaneously	O
activating	O
the	O
expression	O
of	O
B-lineage-specific	O
genes	O
.	O
Pax5	O
thus	O
functions	O
both	O
as	O
a	O
transcriptional	O
repressor	O
and	O
activator	O
,	O
depending	O
on	O
its	O
interactions	O
with	O
corepressors	O
of	O
the	O
Groucho	B-protein
protein	I-protein
family	I-protein
or	O
with	O
positive	O
regulators	O
such	O
as	O
the	O
TATA-binding	B-protein
protein	I-protein
.	O
Once	O
committed	O
to	O
the	O
B-lineage	O
,	O
B	O
cells	O
require	O
Pax5	O
function	O
to	O
maintain	O
their	O
B-lymphoid	O
identity	O
throughout	O
B	O
cell	O
development	O
Partners	O
in	O
transcription	O
:	O
NFAT	O
and	O
AP-1	B-protein
.	O
Combinatorial	O
regulation	O
is	O
a	O
powerful	O
mechanism	O
that	O
enables	O
tight	O
control	O
of	O
gene	O
expression	O
,	O
via	O
integration	O
of	O
multiple	O
signaling	O
pathways	O
that	O
induce	O
different	O
transcription	B-protein
factors	I-protein
required	O
for	O
enhanceosome	O
assembly	O
.	O
The	O
four	O
calcium-regulated	O
transcription	B-protein
factors	I-protein
of	O
the	O
NFAT	B-protein
family	I-protein
act	O
synergistically	O
with	O
AP-1	B-protein
(	O
Fos/Jun	B-protein
)	I-protein
proteins	I-protein
on	O
composite	O
DNA	O
elements	O
which	O
contain	O
adjacent	O
NFAT	O
and	O
AP-1	O
binding	O
sites	O
,	O
where	O
they	O
form	O
highly	O
stable	O
ternary	O
complexes	O
to	O
regulate	O
the	O
expression	O
of	O
diverse	O
inducible	O
genes	O
.	O
Concomitant	O
induction	O
of	O
NFAT	B-protein
and	O
AP-1	B-protein
requires	O
concerted	O
activation	O
of	O
two	O
different	O
signaling	O
pathways	O
:	O
calcium/calcineurin	O
,	O
which	O
promotes	O
NFAT	O
dephosphorylation	O
,	O
nuclear	O
translocation	O
and	O
activation	O
;	O
and	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
/Ras	O
,	O
which	O
promotes	O
the	O
synthesis	O
,	O
phosphorylation	O
and	O
activation	O
of	O
members	O
of	O
the	O
Fos	O
and	O
Jun	O
families	O
of	O
transcription	B-protein
factors	I-protein
.	O
A	O
fifth	O
member	O
of	O
the	O
NFAT	B-protein
family	I-protein
,	O
NFAT5	O
,	O
controls	O
the	O
cellular	O
response	O
to	O
osmotic	O
stress	O
,	O
by	O
a	O
mechanism	O
that	O
requires	O
dimer	O
formation	O
and	O
is	O
independent	O
of	O
calcineurin	B-protein
or	O
of	O
interaction	O
with	O
AP-1	B-protein
.	O
Pharmacological	O
interference	O
with	O
theNFAT	O
:	O
AP-1	O
interaction	O
may	O
be	O
useful	O
in	O
selective	O
manipulation	O
of	O
the	O
immune	O
response	O
.	O
Balanced	O
activation	O
of	O
NFAT	B-protein
and	O
AP-1	B-protein
is	O
known	O
to	O
be	O
required	O
for	O
productive	O
immune	O
responses	O
,	O
but	O
the	O
role	O
of	O
NFAT	B-protein
:	O
AP-1	O
interactions	O
in	O
other	O
cell	O
types	O
and	O
biological	O
processes	O
remains	O
to	O
be	O
understood	O
.	O
Cytokine	O
production	O
by	O
Vgamma	O
(	O
+	O
)	O
-T-cell	O
subsets	O
is	O
an	O
important	O
factor	O
determining	O
CD4	O
(	O
+	O
)	O
-Th-cell	O
phenotype	O
and	O
susceptibility	O
of	O
BALB/c	O
mice	O
to	O
coxsackievirus	O
B3-induced	O
myocarditis	O
.	O
Two	O
coxsackievirus	O
B3	O
(	O
CVB3	O
)	O
variants	O
(	O
H3	O
and	O
H310A1	O
)	O
differ	O
by	O
a	O
single	O
amino	O
acid	O
mutation	O
in	O
the	O
VP2	B-protein
capsid	I-protein
protein	I-protein
.	O
H3	O
induces	O
severe	O
myocarditis	O
in	O
BALB/c	O
mice	O
,	O
but	O
H310A1	O
is	O
amyocarditic	O
.	O
Infection	O
with	O
H3	O
,	O
but	O
not	O
H310A1	O
,	O
preferentially	O
activates	O
Vgamma4	O
Vdelta4	O
cells	O
,	O
which	O
are	O
strongly	O
positive	O
for	O
gamma	B-protein
interferon	I-protein
(	O
IFN-gamma	B-protein
)	O
,	O
whereas	O
Vgamma1	O
Vdelta4	O
cells	O
are	O
increased	O
in	O
both	O
H3	O
and	O
H310A1	O
virus-infected	O
animals	O
.	O
Depletion	O
of	O
Vgamma1	O
(	O
+	O
)	O
cells	O
using	O
monoclonal	B-protein
anti-Vgamma1	I-protein
antibody	I-protein
enhanced	O
myocarditis	O
and	O
CD4	O
(	O
+	O
)	O
-	O
,	O
IFN-gamma	B-protein
(	O
+	O
)	O
-cell	O
responses	O
in	O
both	O
H3-	O
and	O
H310A1-infected	O
mice	O
yet	O
decreased	O
the	O
CD4	O
(	O
+	O
)	O
-	O
,	O
IL-4	B-protein
(	O
+	O
)	O
-cell	O
response	O
.	O
Depleting	O
Vgamma4	O
(	O
+	O
)	O
cells	O
suppressed	O
myocarditis	O
and	O
reduced	O
CD4	O
(	O
+	O
)	O
IFN-gamma	O
(	O
+	O
)	O
cells	O
but	O
increased	O
CD4	O
(	O
+	O
)	O
IL-4	B-protein
(	O
+	O
)	O
T	O
cells	O
.	O
The	O
role	O
of	O
cytokine	B-protein
production	O
by	O
Vgamma1	O
(	O
+	O
)	O
and	O
Vgamma4	O
(	O
+	O
)	O
T	O
cells	O
was	O
investigated	O
by	O
adoptively	O
transferring	O
these	O
cells	O
isolated	O
from	O
H3-infected	O
BALB/c	O
Stat4	O
knockout	O
(	O
Stat4ko	O
)	O
(	O
defective	O
in	O
IFN-gamma	O
expression	O
)	O
or	O
BALB/c	O
Stat6ko	O
(	O
defective	O
in	O
IL-4	O
expression	O
)	O
mice	O
into	O
H3	O
virus-infected	O
wild-type	O
BALB/c	O
recipients	O
.	O
Vgamma4	O
and	O
Vgamma1	O
(	O
+	O
)	O
T	O
cells	O
from	O
Stat4ko	O
mice	O
expressed	O
IL-4	B-protein
but	O
no	O
or	O
minimal	O
IFN-gamma	O
,	O
whereas	O
these	O
cell	O
populations	O
derived	O
from	O
Stat6ko	O
mice	O
expressed	O
IFN-gamma	B-protein
but	O
no	O
IL-4	B-protein
.	O
Stat4ko	O
Vgamma1	O
(	O
+	O
)	O
cells	O
(	O
IL-4	B-protein
(	O
+	O
)	O
)	O
suppress	O
myocarditis	O
.	O
Stat6ko	O
Vgamma1	O
(	O
+	O
)	O
cells	O
(	O
IFN-gamma	B-protein
(	O
+	O
)	O
)	O
were	O
not	O
inhibitory	O
.	O
Stat6ko	O
Vgamma4	O
(	O
+	O
)	O
cells	O
(	O
IFN-gamma	B-protein
(	O
+	O
)	O
)	O
significantly	O
enhanced	O
myocarditis	O
.	O
Stat4ko	O
Vgamma4	O
(	O
+	O
)	O
cells	O
(	O
IL-4	B-protein
(	O
+	O
)	O
)	O
neither	O
inhibited	O
nor	O
enhanced	O
disease	O
.	O
These	O
results	O
show	O
that	O
distinct	O
gammadelta-T-cell	O
subsets	O
control	O
myocarditis	O
susceptibility	O
and	O
bias	O
the	O
CD4	O
(	O
+	O
)	O
-Th-cell	O
response	O
.	O
The	O
cytokines	B-protein
produced	O
by	O
the	O
Vgamma	O
subpopulation	O
have	O
a	O
significant	O
influence	O
on	O
the	O
CD4	O
(	O
+	O
)	O
-Th-cell	O
phenotype	O
.	O
Plasmin	B-protein
-induced	O
expression	O
of	O
cytokines	B-protein
and	O
tissue	B-protein
factor	I-protein
in	O
human	O
monocytes	O
involves	O
AP-1	B-protein
and	O
IKKbeta	B-protein
-mediated	O
NF-kappaB	O
activation	O
.	O
It	O
was	O
previously	O
shown	O
that	O
plasmin	B-protein
activates	O
human	O
peripheral	O
monocytes	O
in	O
terms	O
of	O
lipid	O
mediator	O
release	O
and	O
chemotactic	O
migration	O
.	O
Here	O
it	O
is	O
demonstrated	O
that	O
plasmin	O
induces	O
proinflammatory	O
cytokine	O
release	O
and	O
tissue	B-protein
factor	I-protein
(	O
TF	O
)	O
expression	O
by	O
monocytes	O
.	O
Plasmin	O
0.043	O
to	O
1.43	O
CTA	O
U/mL	O
,	O
but	O
not	O
active	O
site-blocked	O
plasmin	O
,	O
triggered	O
concentration-dependent	O
expression	O
of	O
mRNA	O
for	O
interleukin-1alpha	O
(	O
IL-1alpha	B-protein
)	O
,	O
IL-1beta	B-protein
,	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
,	O
and	O
TF	O
with	O
maximum	O
responses	O
after	O
4	O
hours	O
.	O
Plasmin	B-protein
-mediated	O
mRNA	O
expression	O
was	O
inhibited	O
in	O
a	O
concentration-dependent	O
manner	O
by	O
the	O
lysine	O
analogue	O
trans-4-	O
(	O
aminomethyl	O
)	O
cyclohexane-1-carboxylic	O
acid	O
(	O
t-AMCA	O
)	O
.	O
Increases	O
in	O
mRNA	O
levels	O
were	O
followed	O
by	O
concentration-	O
and	O
time-dependent	O
release	O
of	O
IL-1alpha	B-protein
,	O
IL-1beta	B-protein
and	O
TNF-alpha	B-protein
and	O
by	O
TF	O
expression	O
on	O
monocyte	O
surfaces	O
.	O
Neither	O
cytokines	B-protein
nor	O
TF	B-protein
could	O
be	O
detected	O
when	O
monocytes	O
were	O
preincubated	O
with	O
actinomycin	O
D	O
or	O
cycloheximide	O
.	O
Electrophoretic	O
mobility	O
shift	O
assays	O
indicated	O
plasmin	B-protein
-induced	O
activation	O
of	O
NF-kappaB	B-protein
;	O
DNA-binding	B-protein
complexes	I-protein
were	O
composed	O
of	O
p50	B-protein
,	O
p65	B-protein
,	O
and	O
c-Rel	B-protein
,	O
as	O
shown	O
by	O
supershift	O
experiments	O
.	O
Nuclear	O
translocation	O
of	O
NF-kappaB/Rel	B-protein
proteins	I-protein
coincided	O
with	O
IkappaBalpha	O
degradation	O
.	O
At	O
variance	O
with	O
endotoxic	O
lipopolysaccharide	O
,	O
plasmin	O
elicited	O
the	O
rapid	O
degradation	O
of	O
another	O
cytoplasmic	O
NF-kappaB	O
inhibitor	O
,	O
p105	B-protein
.	O
Proteolysis	O
of	O
NF-kappaB	B-protein
inhibitors	O
was	O
apparently	O
due	O
to	O
transient	O
activation	O
of	O
IkappaB	B-protein
kinase	I-protein
(	I-protein
IKK	I-protein
)	I-protein
beta	I-protein
that	O
reached	O
maximum	O
activity	O
at	O
1	O
hour	O
after	O
plasmin	O
stimulation	O
.	O
In	O
addition	O
,	O
AP-1	O
binding	O
was	O
increased	O
in	O
plasmin	O
-treated	O
monocytes	O
,	O
with	O
most	O
complexes	O
composed	O
of	O
JunD	B-protein
,	O
c-Fos	B-protein
,	O
and	O
FosB	O
.	O
These	O
findings	O
further	O
substantiate	O
the	O
role	O
of	O
plasmin	B-protein
as	O
a	O
proinflammatory	B-protein
activator	I-protein
of	O
human	O
monocytes	O
and	O
reveal	O
an	O
important	O
new	O
link	O
between	O
the	O
plasminogen-plasmin	O
system	O
and	O
inflammation	O
.	O
(	O
2001	O
;	O
97	O
:	O
3941-3950	O
)	O
STAT3	B-protein
is	O
constitutively	O
active	O
in	O
some	O
patients	O
with	O
Polycythemia	O
rubra	O
vera	O
.	O
OBJECTIVE	O
:	O
Polycythemia	O
vera	O
is	O
a	O
clonal	O
stem	O
cell	O
disorder	O
characterized	O
by	O
hyperproliferation	O
of	O
the	O
erythroid	O
,	O
myeloid	O
,	O
and	O
megakaryocytic	O
lineages	O
.	O
While	O
it	O
has	O
been	O
shown	O
that	O
progenitor	O
cells	O
of	O
P.	O
vera	O
patients	O
are	O
hypersensitive	O
to	O
several	O
growth	O
factors	O
including	O
erythropoietin	B-protein
,	O
insulin-like	B-protein
growth	I-protein
factor-1	I-protein
,	O
thrombopoietin	B-protein
,	O
interleukin-3	O
,	O
and	O
granulocyte/monocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
,	O
the	O
molecular	O
pathogenesis	O
of	O
this	O
disease	O
remains	O
unknown	O
.	O
Growth	B-protein
factor	I-protein
hypersensitivity	I-protein
could	O
be	O
mediated	O
by	O
changes	O
in	O
signal	O
transduction	O
pathways	O
.	O
We	O
therefore	O
investigated	O
a	O
common	O
downstream	O
effector	O
of	O
cytokines	B-protein
,	O
the	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STATs	B-protein
)	O
.	O
A	O
constitutive	O
activation	O
of	O
STAT	B-protein
factors	I-protein
could	O
explain	O
the	O
increased	O
proliferation	O
of	O
P.	O
vera	O
cells	O
even	O
in	O
the	O
absence	O
of	O
growth	O
factor	O
stimulation	O
.	O
METHODS	O
:	O
Peripheral	O
granulocytes	O
from	O
patients	O
with	O
P.	O
vera	O
and	O
from	O
healthy	O
volunteers	O
were	O
assayed	O
for	O
STAT1	B-protein
,	O
3	O
,	O
and	O
5	O
DNA	O
binding	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O
RESULTS	O
:	O
Four	O
of	O
14	O
P.	O
vera	O
patients	O
analyzed	O
showed	O
constitutive	O
STAT3	O
DNA	O
binding	O
in	O
unstimulated	O
peripheral	O
granulocytes	O
,	O
while	O
none	O
of	O
the	O
17	O
healthy	O
volunteers	O
tested	O
did	O
.	O
None	O
of	O
the	O
subjects	O
showed	O
constitutive	O
STAT1	B-protein
or	O
STAT5	B-protein
activity	O
.	O
Western	O
blotting	O
demonstrated	O
that	O
,	O
in	O
the	O
three	O
patients	O
,	O
STAT3	B-protein
is	O
constitutively	O
phosphorylated	O
on	O
Tyr	O
705	O
,	O
whereas	O
it	O
is	O
unphosphorylated	O
in	O
the	O
other	O
patients	O
and	O
in	O
controls	O
.	O
Interestingly	O
,	O
constitutive	O
STAT3	B-protein
activity	O
did	O
not	O
correlate	O
with	O
the	O
duration	O
of	O
disease	O
or	O
the	O
treatment	O
regimen	O
.	O
It	O
was	O
observed	O
in	O
a	O
recently	O
diagnosed	O
patient	O
and	O
in	O
two	O
patients	O
treated	O
only	O
with	O
phlebotomy	O
.	O
CONCLUSION	O
:	O
Our	O
data	O
suggest	O
that	O
constitutive	O
phosphorylation	O
and	O
activation	O
of	O
STAT3	B-protein
is	O
not	O
a	O
secondary	O
event	O
induced	O
by	O
mutagenizing	O
agents	O
or	O
by	O
prolonged	O
hyperproliferation	O
of	O
hematopoietic	O
cells	O
,	O
but	O
rather	O
represents	O
a	O
primary	O
molecular	O
aberration	O
.	O
Constitutively	O
active	O
STAT3	B-protein
may	O
contribute	O
to	O
the	O
growth	B-protein
factor	I-protein
hypersensitivity	O
of	O
P.	O
vera	O
cells	O
.	O
Identification	O
of	O
phosphorylation	O
sites	O
for	O
Bruton	B-protein
's	I-protein
tyrosine	I-protein
kinase	I-protein
within	O
the	O
transcriptional	B-protein
regulator	I-protein
BAP/TFII-I	I-protein
.	O
Bruton	B-protein
's	I-protein
tyrosine	I-protein
kinase	I-protein
(	O
Btk	B-protein
)	O
,	O
a	O
member	O
of	O
the	O
Tec	O
family	O
of	O
cytosolic	B-protein
kinases	I-protein
,	O
is	O
essential	O
for	O
B	O
cell	O
development	O
and	O
function	O
.	O
BAP/TFII-I	O
,	O
a	O
protein	O
implicated	O
in	O
transcriptional	O
regulation	O
,	O
is	O
associated	O
with	O
Btk	B-protein
in	O
B	O
cells	O
and	O
is	O
transiently	O
phosphorylated	O
on	O
tyrosine	O
following	O
B	O
cell	O
receptor	O
engagement	O
.	O
BAP/TFII-I	O
is	O
a	O
substrate	O
for	O
Btk	B-protein
in	O
vitro	O
and	O
is	O
hyperphosphorylated	O
on	O
tyrosine	O
upon	O
coexpression	O
with	O
Btk	B-protein
in	O
mammalian	O
cells	O
.	O
In	O
an	O
effort	O
to	O
understand	O
the	O
physiologic	O
consequences	O
of	O
BAP/TFII-I	O
tyrosine	O
phosphorylation	O
following	O
B	O
cell	O
receptor	O
stimulation	O
,	O
site-directed	O
mutagenesis	O
and	O
phosphopeptide	O
mapping	O
were	O
used	O
to	O
locate	O
the	O
predominant	O
sites	O
of	O
BAP/TFII-I	O
phosphorylation	O
by	O
Btk	B-protein
in	O
vitro	O
.	O
These	O
residues	O
,	O
Tyr248	O
,	O
Tyr357	O
,	O
and	O
Tyr462	O
,	O
were	O
also	O
found	O
to	O
be	O
the	O
major	O
sites	O
for	O
Btk	B-protein
-dependent	O
phosphorylation	O
of	O
BAP/TFII-I	O
in	O
vivo	O
.	O
Residues	B-protein
Tyr357	I-protein
and	O
Tyr462	O
are	O
contained	O
within	O
the	O
loop	O
regions	O
of	O
adjacent	O
helix-loop-helix-like	O
repeats	O
within	O
BAP/TFII-I	O
.	O
Mutation	O
of	O
either	O
Tyr248	O
,	O
Tyr357	O
,	O
or	O
Tyr462	O
to	O
phenylalanine	O
reduced	O
transcription	O
from	O
a	O
c-fos	O
promoter	O
relative	O
to	O
wild-type	B-protein
BAP/TFII-I	I-protein
in	O
transfected	O
COS-7	O
cells	O
,	O
consistent	O
with	O
the	O
interpretation	O
that	O
phosphorylation	O
at	O
these	O
sites	O
contributes	O
to	O
transcriptional	O
activation	O
.	O
Phosphorylation	O
of	O
BAP/TFII-I	O
by	O
Btk	B-protein
may	O
link	O
engagement	O
of	O
receptors	O
such	O
as	O
surface	O
immunoglobulin	O
to	O
modulation	O
of	O
gene	O
expression	O
.	O
Expression	O
of	O
interferon	B-protein
consensus	I-protein
sequence	I-protein
binding	I-protein
protein	I-protein
induces	O
potent	O
immunity	O
against	O
BCR/ABL-induced	O
leukemia	O
.	O
Mice	O
deficient	O
in	O
the	O
interferon	B-protein
consensus	I-protein
sequence	I-protein
binding	I-protein
protein	I-protein
(	O
ICSBP	B-protein
)	O
develop	O
a	O
disease	O
resembling	O
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
,	O
which	O
in	O
humans	O
is	O
caused	O
by	O
the	O
BCR/ABL	B-protein
oncoprotein	I-protein
.	O
Interferon-alpha	B-protein
(	O
IFN-alpha	B-protein
)	O
induces	O
ICSBP	B-protein
expression	O
and	O
is	O
an	O
effective	O
therapy	O
for	O
CML	O
.	O
This	O
study	O
examined	O
whether	O
enforced	O
expression	O
of	O
ICSBP	B-protein
might	O
antagonize	O
BCR/ABL-induced	O
leukemia	O
;	O
results	O
demonstrated	O
that	O
ICSBP-modified	O
cells	O
generated	O
a	O
protective	O
CD8	O
(	O
+	O
)	O
cytotoxic	O
T-cell	O
response	O
against	O
BCR/ABL-transformed	O
BaF3	O
cells	O
in	O
a	O
murine	O
leukemia	O
model	O
.	O
ICSBP	B-protein
expression	O
represents	O
a	O
novel	O
means	O
of	O
stimulating	O
a	O
host	O
immune	O
response	O
to	O
BCR/ABL	O
(	O
+	O
)	O
leukemia	O
cells	O
and	O
a	O
potential	O
strategy	O
for	O
immunotherapy	O
of	O
CML	O
.	O
(	O
2001	O
;	O
97	O
:	O
3491-3497	O
)	O
A	O
transcriptional	O
block	O
in	O
the	O
IL-2	O
promoter	O
at	O
the	O
-150	O
AP-1	O
site	O
in	O
effector	O
CD8+	O
T	O
cells	O
.	O
Both	O
CD4+	O
and	O
CD8+	O
T	O
cells	O
that	O
produce	O
IL-2	B-protein
in	O
response	O
to	O
Ag	O
recognition	O
have	O
been	O
isolated	O
.	O
However	O
,	O
most	O
effector	O
CD8+	O
T	O
cells	O
recovered	O
after	O
exposure	O
to	O
Ag	O
do	O
not	O
produce	O
sufficient	O
IL-2	O
to	O
sustain	O
growth	O
,	O
and	O
depend	O
on	O
CD4+	O
T	O
helper	O
cells	O
for	O
this	O
obligate	B-protein
growth	I-protein
factor	I-protein
.	O
IL-2	O
expression	O
in	O
CD4+	O
T	O
cells	O
is	O
primarily	O
controlled	O
at	O
the	O
level	O
of	O
transcription	O
,	O
but	O
mechanisms	O
restricting	O
IL-2	O
production	O
in	O
CD8+	O
T	O
cells	O
have	O
not	O
been	O
elucidated	O
.	O
To	O
evaluate	O
transcriptional	O
regulation	O
of	O
the	O
IL-2	O
gene	O
in	O
CD8+	O
T	O
cells	O
,	O
we	O
stably	O
transfected	O
reporter	O
genes	O
into	O
Ag	O
-specific	O
CD8+	O
T	O
cell	O
clones	O
.	O
CD28+	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
unable	O
to	O
transcribe	O
the	O
IL-2	O
gene	O
in	O
response	O
to	O
antigenic	O
stimulation	O
had	O
a	O
block	O
in	O
transactivation	O
of	O
the	O
-150	O
CD28	O
response	O
element	O
(	O
CD28RE	O
)	O
/AP-1	O
site	O
of	O
the	O
IL-2	O
promoter	O
,	O
but	O
did	O
transactivate	O
the	O
composite	O
NFAT/AP-1	O
and	O
OCT/AP-1	O
sites	O
,	O
and	O
a	O
consensus	O
AP-1	O
motif	O
.	O
Mutation	O
of	O
the	O
nonconsensus	O
-150	O
AP-1	O
site	O
to	O
a	O
consensus	O
AP-1	O
site	O
,	O
or	O
insertion	O
of	O
a	O
CD28RE/AP-1	O
consensus	O
site	O
upstream	O
of	O
the	O
native	O
-150	O
CD28RE/AP-1	O
site	O
restored	O
transactivation	O
of	O
the	O
altered	O
promoter	O
.	O
These	O
results	O
suggest	O
that	O
the	O
defect	O
at	O
the	O
-150	O
site	O
may	O
reflect	O
the	O
absence	O
or	O
inactivity	O
of	O
a	O
required	O
factor	O
rather	O
than	O
repression	O
of	O
the	O
IL-2	O
promoter	O
.	O
Stem	B-protein
cell	I-protein
factor	I-protein
and	O
interleukin-3	O
induce	O
stepwise	O
generation	O
of	O
erythroid	O
precursor	O
cells	O
from	O
a	O
basic	B-protein
fibroblast	I-protein
growth	I-protein
factor	I-protein
-dependent	O
hematopoietic	O
stem	O
cell	O
line	O
,	O
A-6	O
.	O
A	O
m	O
ultipotent	O
immature	O
myeloid	O
cell	O
population	O
was	O
produced	O
from	O
a	O
basic	B-protein
fibroblast	I-protein
growth	I-protein
factor	I-protein
(	O
bFGF	O
)	O
-dependent	O
hematopoietic	O
stem	O
cell	O
line	O
,	O
A-6	O
,	O
when	O
cultured	O
with	O
stem	B-protein
cell	I-protein
factor	I-protein
(	O
SCF	B-protein
)	O
replacing	O
bFGF	O
.	O
Those	O
cells	O
were	O
positive	O
for	O
stem	O
cell	O
markers	O
,	O
c-kit	O
and	O
CD34	O
,	O
and	O
a	O
myeloid	O
cell	O
marker	O
,	O
F4/80	O
.	O
Some	O
cell	O
fractions	O
were	O
also	O
positive	O
for	O
Mac-1	O
,	O
a	O
macrophage	O
marker	O
or	O
Gr-1	O
,	O
a	O
granulocytic	O
maker	O
,	O
but	O
negative	O
for	O
an	O
erythroid	O
marker	O
TER119	O
.	O
They	O
also	O
showed	O
the	O
expression	O
of	O
mRNA	O
for	O
the	O
myeloid-specific	O
PU.1	O
but	O
did	O
not	O
that	O
for	O
the	O
erythroid-specific	O
GATA-1	O
.	O
Among	O
various	O
cytokines	B-protein
,	O
interleukin-3	O
(	O
IL-3	B-protein
)	O
induced	O
erythroid	O
precursor	O
cells	O
that	O
expressed	O
the	O
erythroid-specific	O
GATA-1	O
and	O
beta-major	O
globin	O
.	O
The	O
quantitative	O
analysis	O
showed	O
that	O
erythroid	O
precursor	O
cells	O
were	O
newly	O
produced	O
from	O
the	O
immature	O
myeloid	O
cells	O
by	O
cultivation	O
with	O
IL-3	B-protein
.	O
SCF	B-protein
and	O
IL-3	B-protein
induced	O
stepwise	O
generation	O
of	O
erythroid	O
precursor	O
cells	O
from	O
an	O
A-6	O
hematopoietic	O
stem	O
cell	O
line	O
.	O
Copyright	O
2001	O
Academic	O
Press	O
.	O
Distinct	O
BMI-1	O
and	O
EZH2	O
expression	O
patterns	O
in	O
thymocytes	O
and	O
mature	O
T	O
cells	O
suggest	O
a	O
role	O
for	O
Polycomb	O
genes	O
in	O
human	O
T	O
cell	O
differentiation	O
.	O
BMI-1	O
and	O
EZH2	O
Polycomb-group	O
(	O
PcG	B-protein
)	I-protein
proteins	I-protein
belong	O
to	O
two	O
distinct	O
protein	O
complexes	O
involved	O
in	O
the	O
regulation	O
of	O
hematopoiesis	O
.	O
Using	O
unique	O
PcG-specific	O
antisera	O
and	O
triple	O
immunofluorescence	O
,	O
we	O
found	O
that	O
mature	O
resting	O
peripheral	O
T	O
cells	O
expressed	O
BMI-1	O
,	O
whereas	O
dividing	O
blasts	O
were	O
EZH2	O
(	O
+	O
)	O
.	O
By	O
contrast	O
,	O
subcapsular	O
immature	O
double-negative	O
(	O
DN	O
)	O
(	O
CD4	O
(	O
-	O
)	O
/CD8	O
(	O
-	O
)	O
)	O
T	O
cells	O
in	O
the	O
thymus	O
coexpressed	O
BMI-1	O
and	O
EZH2	O
or	O
were	O
BMI-1	O
single	O
positive	O
.	O
Their	O
descendants	O
,	O
double-positive	O
(	O
DP	O
;	O
CD4	O
(	O
+	O
)	O
/CD8	O
(	O
+	O
)	O
)	O
cortical	O
thymocytes	O
,	O
expressed	O
EZH2	O
without	O
BMI-1	O
.	O
Most	O
EZH2	O
(	O
+	O
)	O
DN	O
and	O
DP	O
thymocytes	O
were	O
dividing	O
,	O
while	O
DN	O
BMI-1	O
(	O
+	O
)	O
/EZH2	O
(	O
-	O
)	O
thymocytes	O
were	O
resting	O
and	O
proliferation	O
was	O
occasionally	O
noted	O
in	O
DN	O
BMI-1	O
(	O
+	O
)	O
/EZH2	O
(	O
+	O
)	O
cells	O
.	O
Maturation	O
of	O
DP	O
cortical	O
thymocytes	O
to	O
single-positive	O
(	O
CD4	O
(	O
+	O
)	O
/CD8	O
(	O
-	O
)	O
or	O
CD8	O
(	O
+	O
)	O
/CD4	O
(	O
-	O
)	O
)	O
medullar	O
thymocytes	O
correlated	O
with	O
decreased	O
detectability	O
of	O
EZH2	B-protein
and	O
continued	O
relative	O
absence	O
of	O
BMI-1	O
.	O
Our	O
data	O
show	O
that	O
BMI-1	O
and	O
EZH2	O
expression	O
in	O
mature	O
peripheral	O
T	O
cells	O
is	O
mutually	O
exclusive	O
and	O
linked	O
to	O
proliferation	O
status	O
,	O
and	O
that	O
this	O
pattern	O
is	O
not	O
yet	O
established	O
in	O
thymocytes	O
of	O
the	O
cortex	O
and	O
medulla	O
.	O
T	O
cell	O
stage-specific	O
PcG	O
expression	O
profiles	O
suggest	O
that	O
PcG	O
genes	O
contribute	O
to	O
regulation	O
of	O
T	O
cell	O
differentiation	O
.	O
They	O
probably	O
reflect	O
stabilization	O
of	O
cell	O
type-specific	O
gene	O
expression	O
and	O
irreversibility	O
of	O
lineage	O
choice	O
.	O
The	O
difference	O
in	O
PcG	O
expression	O
between	O
medullar	O
thymocytes	O
and	O
mature	O
interfollicular	O
T	O
cells	O
indicates	O
that	O
additional	O
maturation	O
processes	O
occur	O
after	O
thymocyte	O
transportation	O
from	O
the	O
thymus	O
.	O
Stepwise	O
lineage	O
restriction	O
of	O
progenitors	O
in	O
lympho-myelopoiesis	O
.	O
It	O
has	O
long	O
been	O
controversial	O
whether	O
hematopoiesis	O
progresses	O
through	O
ordered	O
stages	O
of	O
determination	O
as	O
in	O
embryonic	O
development	O
.	O
This	O
is	O
due	O
to	O
the	O
absence	O
of	O
a	O
methodology	O
capable	O
of	O
exactly	O
determining	O
the	O
developmental	O
potential	O
of	O
hematopoietic	O
stem/progenitor	O
cells	O
.	O
The	O
multilineage	O
progenitor	O
(	O
MLP	O
)	O
assay	O
enabled	O
us	O
to	O
discriminate	O
among	O
seven	O
types	O
of	O
hematopoietic	O
progenitors	O
,	O
which	O
are	O
multipotent	O
progenitor	O
p-MTB	O
(	O
capable	O
of	O
generating	O
myeloid	O
,	O
T	O
and	O
B	O
cells	O
)	O
,	O
bipotent	O
progenitors	O
p-MT	O
,	O
p-MB	O
and	O
p-TB	O
,	O
and	O
unipotent	O
progenitors	O
p-M	O
,	O
p-T	O
and	O
p-B	O
.	O
Among	O
these	O
seven	O
types	O
,	O
the	O
p-TB	O
type	O
progenitor	O
was	O
found	O
to	O
be	O
absent	O
.	O
These	O
findings	O
indicate	O
that	O
the	O
process	O
of	O
lineage	O
commitment	O
proceeds	O
through	O
an	O
ordered	O
but	O
not	O
random	O
process	O
.	O
By	O
extending	O
the	O
area	O
of	O
investigation	O
to	O
include	O
the	O
erythroid	O
lineage	O
,	O
more	O
convincing	O
evidence	O
for	O
the	O
ordered	O
process	O
was	O
obtained	O
.	O
Detailed	O
and	O
exact	O
illustration	O
of	O
the	O
process	O
of	O
hematopoiesis	O
will	O
provide	O
an	O
opportunity	O
to	O
revive	O
hematopoiesis	O
as	O
one	O
of	O
the	O
most	O
fascinating	O
targets	O
of	O
research	O
in	O
developmental	O
biology	O
Epstein-Barr	O
Virus	O
and	O
its	O
glycoprotein-350	O
upregulate	O
IL-6	B-protein
in	O
human	O
B-lymphocytes	O
via	O
CD21	O
,	O
involving	O
activation	O
of	O
NF-kappaB	B-protein
and	O
different	O
signaling	O
pathways	O
.	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
a	O
ubiquitous	O
and	O
highly	O
immunotropic	O
gamma	O
herpesvirus	O
that	O
infects	O
more	O
than	O
90	O
%	O
of	O
humans	O
worldwide	O
.	O
Its	O
pathogenicity	O
leads	O
to	O
a	O
number	O
of	O
diseases	O
including	O
tumors	O
that	O
result	O
from	O
EBV	O
's	O
ability	O
to	O
readily	O
transform	O
B-lymphocytes	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
epithelial	O
cells	O
.	O
EBV	O
utilizes	O
CD21/CR2	O
as	O
its	O
receptor	O
on	O
B	O
cells	O
to	O
initiate	O
the	O
infection	O
process	O
.	O
EBV	O
binds	O
to	O
CR2	O
through	O
its	O
major	B-protein
envelope	I-protein
glycoprotein-350	I-protein
(	O
gp350	O
)	O
and	O
is	O
also	O
a	O
remarkable	O
immunomodulating	O
agent	O
.	O
We	O
had	O
previously	O
shown	O
that	O
EBV	O
is	O
capable	O
of	O
modulating	O
the	O
synthesis	O
of	O
a	O
number	O
of	O
cytokines	B-protein
.	O
We	O
now	O
show	O
that	O
while	O
both	O
purified	O
recombinant	O
gp350	O
(	O
rgp350	O
)	O
and	O
EBV	O
upregulate	O
IL-6	O
mRNA	O
synthesis	O
in	O
B	O
cells	O
,	O
EBV-induced	O
IL-6	O
gene	O
activation	O
occurs	O
for	O
a	O
significantly	O
longer	O
period	O
of	O
time	O
(	O
12	O
hours	O
for	O
EBV	O
as	O
compared	O
to	O
6	O
hours	O
for	O
rgp350	O
)	O
.	O
Moreover	O
,	O
the	O
half-life	O
of	O
EBV-induced	O
IL-6	O
mRNA	O
was	O
also	O
significantly	O
longer	O
(	O
10	O
hours	O
)	O
than	O
that	O
of	O
mRNA	O
induced	O
by	O
rgp350	O
(	O
about	O
6	O
hours	O
)	O
.	O
Both	O
EBV	O
and	O
gp350	O
enhance	O
the	O
binding	O
of	O
the	O
NF-kappaB	B-protein
transcription	I-protein
factor	I-protein
,	O
as	O
determined	O
by	O
band-shift	O
and	O
augment	O
NF-kappaB	B-protein
-mediated	O
activation	O
of	O
a	O
CAT	O
reporter	O
plasmid	O
.	O
Furthermore	O
,	O
we	O
demonstrate	O
that	O
while	O
the	O
activation	O
of	O
IL-6	O
gene	O
expression	O
by	O
gp350	O
is	O
mediated	O
primarily	O
by	O
the	O
protein	B-protein
kinase	I-protein
C	I-protein
pathway	O
,	O
EBV	O
can	O
mediate	O
its	O
effects	O
through	O
multiple	O
signaling	O
pathways	O
.	O
To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
report	O
showing	O
that	O
the	O
binding	O
of	O
a	O
herpesvirus	O
envelope	O
glycoprotein	O
to	O
CR2	O
on	O
human	O
B	O
cells	O
results	O
in	O
the	O
activation	O
of	O
the	O
NF-kappaB	B-protein
transcription	I-protein
factor	I-protein
leading	O
to	O
the	O
upregulation	O
of	O
IL-6	O
gene	O
expression	O
in	O
these	O
lymphocytes	O
.	O
Copyright	O
2001	O
Academic	O
Press	O
.	O
Gene-	O
and	O
tissue-specificity	O
of	O
mutation	O
in	O
Big	O
Blue	O
rats	O
treated	O
with	O
the	O
hepatocarcinogen	O
N-hydroxy-2-acetylaminofluorene	O
.	O
In	O
a	O
previous	O
study	O
,	O
we	O
found	O
that	O
treating	O
transgenic	O
Big	O
Blue	O
rats	O
with	O
the	O
hepatocarcinogen	O
N-hydroxy-2-acetylaminofluorene	O
(	O
N-OH-AAF	O
)	O
produced	O
the	O
same	O
major	O
DNA	O
adduct	O
in	O
the	O
target	O
liver	O
and	O
the	O
nontarget	O
spleen	O
lymphocytes	O
and	O
bone	O
marrow	O
cells	O
,	O
induced	O
lacI	O
mutants	O
in	O
the	O
liver	O
,	O
and	O
induced	O
much	O
lower	O
frequencies	O
of	O
l	O
acI	O
and	O
hprt	O
mutants	O
in	O
spleen	O
lymphocytes	O
.	O
In	O
the	O
present	O
study	O
,	O
sequence	O
analysis	O
was	O
conducted	O
on	O
lacI	O
DNA	O
and	O
hprt	O
cDNA	O
from	O
the	O
mutants	O
,	O
to	O
determine	O
the	O
mutational	O
specificity	O
of	O
N-OH-AAF	O
in	O
the	O
rat	O
.	O
All	O
the	O
mutation	O
spectra	O
from	O
N-OH-AAF-treated	O
rats	O
differed	O
significantly	O
from	O
corresponding	O
mutation	O
profiles	O
from	O
untreated	O
animals	O
(	O
P	O
=	O
0.02	O
to	O
P	O
<	O
0.0001	O
)	O
.	O
Although	O
there	O
were	O
similarities	O
among	O
the	O
mutational	O
patterns	O
derived	O
from	O
N-OH-AAF-treated	O
rats	O
(	O
,	O
G	O
:	O
C	O
--	O
>	O
T	O
:	O
A	O
transversion	O
was	O
the	O
most	O
common	O
mutation	O
in	O
all	O
mutation	O
sets	O
)	O
,	O
there	O
were	O
significant	O
differences	O
in	O
the	O
patterns	O
of	O
basepair	O
substitution	O
and	O
frameshift	O
mutation	O
between	O
the	O
liver	O
and	O
spleen	O
lymphocyte	O
lacI	O
mutants	O
(	O
P	O
=	O
0.02	O
)	O
and	O
between	O
the	O
spleen	O
lymphocyte	O
lacI	O
and	O
hprt	O
mutants	O
(	O
P	O
=	O
0.04	O
)	O
.	O
Also	O
,	O
multiplex	O
PCR	O
analysis	O
of	O
genomic	O
DNA	O
from	O
the	O
hprt	O
mutants	O
indicated	O
that	O
12	O
%	O
of	O
mutants	O
from	O
treated	O
rats	O
had	O
major	O
deletions	O
in	O
the	O
hprt	O
gene	O
;	O
no	O
corresponding	O
incidence	O
of	O
large	O
deletions	O
was	O
evident	O
among	O
lacI	O
mutations	O
.	O
All	O
the	O
mutation	O
profiles	O
reflect	O
the	O
general	O
mutational	O
specificity	O
of	O
the	O
major	O
DNA	O
adduct	O
formed	O
by	O
N-OH-AAF	O
.	O
The	O
differences	O
between	O
N-OH-AAF	O
mutation	O
in	O
the	O
endogenous	O
gene	O
and	O
transgene	O
can	O
be	O
partially	O
explained	O
by	O
the	O
structures	O
of	O
the	O
two	O
genes	O
.	O
The	O
tissue-specificity	O
of	O
the	O
mutation	O
spectra	O
may	O
contribute	O
to	O
targeting	O
tumor	O
formation	O
to	O
the	O
liver	O
.	O
37	O
:	O
203-214	O
,	O
2001	O
.	O
Published	O
2001	O
Wiley-Liss	O
,	O
Inc	O
.	O
Caspase	B-protein
-dependent	O
cleavage	O
of	O
the	O
hematopoietic	B-protein
specific	I-protein
adaptor	I-protein
protein	I-protein
Gads	O
alters	O
signalling	O
from	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
.	O
Gads	O
is	O
a	O
SH2	B-protein
and	I-protein
SH3	I-protein
domain	I-protein
-containing	O
,	O
hematopoietic-specific	O
adaptor	O
protein	O
that	O
functions	O
in	O
signalling	O
from	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
.	O
Gads	O
acts	O
by	O
linking	O
SLP-76	O
,	O
bound	O
by	O
the	O
carboxy-terminal	B-protein
Gads	I-protein
SH3	I-protein
domain	I-protein
,	O
to	O
tyrosine	O
phosphorylated	B-protein
LAT	I-protein
which	O
contains	O
binding	O
sites	O
for	O
the	O
Gads	B-protein
SH2	I-protein
domain	I-protein
.	O
Gads	O
is	O
distinguished	O
from	O
Grb2	O
and	O
the	O
closely	O
related	O
Grap	O
protein	O
by	O
the	O
presence	O
of	O
a	O
120	O
amino	O
acid	O
unique	O
region	O
between	O
the	O
SH2	B-protein
domain	I-protein
and	O
the	O
carboxy	B-protein
terminal	I-protein
SH3	I-protein
domain	I-protein
.	O
Here	O
we	O
demonstrate	O
that	O
the	O
unique	O
region	O
of	O
Gads	O
contains	O
a	O
capase	O
cleavage	O
site	O
.	O
Induction	O
of	O
apoptosis	O
in	O
lymphocytes	O
results	O
in	O
detectable	O
Gads	O
cleavage	O
by	O
60	O
min	O
.	O
Gads	O
cleavage	O
is	O
blocked	O
in	O
vivo	O
by	O
treating	O
cells	O
with	O
a	O
caspase	O
3	O
inhibitor	O
.	O
A	O
putative	B-protein
caspase	I-protein
3	I-protein
cleavage	O
site	O
was	O
identified	O
within	O
the	O
unique	O
region	O
and	O
mutation	O
of	O
this	O
site	O
prevented	O
Gads	O
cleavage	O
in	O
vitro	O
,	O
and	O
in	O
vivo	O
.	O
The	O
Gads	O
cleavage	O
products	O
retained	O
the	O
predicted	O
binding	O
specificity	O
for	O
SLP-76	O
and	O
LAT	O
.	O
Expression	O
of	O
the	O
Gads	O
cleavage	O
products	O
in	O
Jurkat	O
T	O
cells	O
inhibited	O
NFAT	O
activation	O
following	O
TCR	O
cross	O
linking	O
.	O
These	O
findings	O
indicate	O
that	O
cleavage	O
of	O
Gads	O
in	O
vivo	O
could	O
function	O
to	O
alter	O
signalling	O
downstream	O
of	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
by	O
disrupting	O
cross	O
talk	O
between	O
SLP-76	O
and	O
LAT	O
.	O
Targeting	O
of	O
p300	B-protein
to	O
the	O
interleukin-2	O
promoter	O
via	O
CREB-Rel	O
cross-talk	O
during	O
mitogen	O
and	O
oncogenic	O
molecular	O
signaling	O
in	O
activated	O
T-cells	O
.	O
In	O
this	O
report	O
,	O
we	O
explore	O
the	O
mechanisms	O
of	O
targeting	O
of	O
p300	B-protein
to	O
the	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
promoter	O
in	O
response	O
to	O
mitogenic	O
and	O
oncogenic	O
molecular	O
signals	O
.	O
Recruitment	O
of	O
p300	B-protein
by	O
cAMP-responsive	O
element-binding	O
protein-Rel	O
cross-talk	O
at	O
the	O
composite	O
CD28	O
response	O
element	O
(	O
CD28RE	O
)	O
-	O
TRE	O
element	O
of	O
the	O
IL-2	O
promoter	O
is	O
essential	O
for	O
promoter	O
inducibility	O
during	O
T-cell	O
activation	O
,	O
and	O
CD28RE-TRE	B-protein
is	O
the	O
exclusive	O
target	O
of	O
the	O
human	B-protein
T-cell	I-protein
lymphotropic	I-protein
virus	I-protein
type	I-protein
I	I-protein
oncoprotein	I-protein
Tax	I-protein
.	O
The	O
intrinsic	O
histone	O
acetyltransferase	O
activity	O
of	O
p300	B-protein
is	O
dispensable	O
for	O
activation	O
of	O
the	O
IL-2	O
promoter	O
,	O
and	O
the	O
N-terminal	O
743	O
residues	O
contain	O
the	O
minimal	O
structural	O
requirements	O
for	O
synergistic	O
transactivation	O
of	O
the	O
CD28RE-TRE	O
,	O
the	O
IL-2	O
promoter	O
,	O
and	O
endogenous	O
IL-2	O
gene	O
expression	O
.	O
Mutational	O
analysis	O
of	O
p300	O
reveals	O
differential	O
structural	O
requirements	O
for	O
the	O
N-terminal	O
p300	O
module	O
by	O
individual	O
cis-elements	O
within	O
the	O
IL-2	O
promoter	O
.	O
These	O
findings	O
provide	O
evidence	O
that	O
p300	O
assembles	O
at	O
the	O
IL-2	O
promoter	O
to	O
form	O
an	O
enhanceosome-like	O
signal	O
transduction	O
target	O
that	O
is	O
centrally	O
integrated	O
at	O
the	O
CD28RE-TRE	O
element	O
of	O
the	O
IL-2	O
promoter	O
through	O
specific	O
protein	O
module-targeted	O
associations	O
in	O
activated	O
T-cells	O
.	O
Regulation	O
of	O
cytokine	B-protein
production	O
in	O
T-cell	O
responses	O
to	O
inhalant	O
allergen	O
:	O
GATA-3	O
expression	O
distinguishes	O
between	O
Th1-	O
and	O
Th2-polarized	O
immunity	O
.	O
BACKGROUND	O
:	O
The	O
precise	O
nature	O
of	O
allergen-specific	O
cytokine	O
responses	O
in	O
atopics	O
versus	O
non-atopics	O
,	O
in	O
particular	O
the	O
'Th1	O
polarity	O
'	O
of	O
responses	O
in	O
non-atopics	O
,	O
remains	O
controversial	O
.	O
This	O
is	O
due	O
in	O
part	O
to	O
the	O
relative	O
insensitivity	O
of	O
cytokine	O
detection	O
systems	O
,	O
and	O
associated	O
variations	O
in	O
kinetics	O
of	O
cytokine	B-protein
production	O
and	O
catabolism	O
in	O
in	O
vitro	O
culture	O
systems	O
.	O
As	O
an	O
alternative	O
to	O
cytokine	O
measurement	O
,	O
this	O
study	O
focuses	O
on	O
expression	O
of	O
the	O
transcription	B-protein
factor	I-protein
GATA-3	I-protein
for	O
analysis	O
of	O
allergen-specific	O
Th	O
cell	O
responses	O
.	O
METHODS	O
:	O
Cord	O
blood	O
mononuclear	O
cells	O
were	O
Th1-	O
or	O
Th2-polarized	O
by	O
culture	O
in	O
IL-12-	O
or	O
IL-4-employing	O
established	O
methods	O
;	O
PBMC	O
from	O
house	O
dust	O
mite	O
(	O
HDM	O
)	O
-sensitive	O
atopics	O
and	O
controls	O
were	O
stimulated	O
overnight	O
with	O
HDM	O
;	O
cytokine	B-protein
production	O
was	O
measured	O
by	O
ELISA	O
and	O
GATA-3	O
mRNA	O
expression	O
by	O
PCR	O
.	O
RESULTS	O
:	O
Cytokine	B-protein
-driven	O
Th2	O
polarization	O
of	O
naive	O
T	O
cells	O
is	O
associated	O
with	O
marked	O
upregulation	O
of	O
GATA-3	B-protein
expression	O
,	O
whereas	O
a	O
reciprocal	O
expression	O
pattern	O
accompanies	O
differentiation	O
towards	O
the	O
Th1	O
cytokine	O
phenotype	O
.	O
In	O
T	O
cells	O
from	O
HDM	O
skin	O
prick	O
test-positive	O
(	O
HDM-SPT+/HDM-IgE+	O
)	O
volunteers	O
,	O
overnight	O
stimulation	O
results	O
in	O
marked	O
upregulation	O
of	O
GATA-3	B-protein
expression	O
,	O
compared	O
to	O
an	O
equally	O
marked	O
downregulation	O
of	O
expression	O
in	O
T	O
cells	O
from	O
SPT-/IgE-	O
subjects	O
.	O
In	O
subjects	O
who	O
are	O
HDM-SPT+	O
but	O
IgE-	O
,	O
GATA-3	B-protein
expression	O
levels	O
remained	O
relatively	O
stable	O
during	O
culture	O
with	O
HDM	O
.	O
CONCLUSIONS	O
:	O
Upregulation	O
of	O
GATA-3	B-protein
expression	O
in	O
PBMC	O
is	O
a	O
hallmark	O
of	O
the	O
early	O
phase	O
of	O
Th2	O
recall	O
responses	O
to	O
specific	O
allergen	O
in	O
atopics	O
.	O
The	O
reciprocal	O
expression	O
pattern	O
observed	O
in	O
HDM-specific	O
recall	O
responses	O
of	O
non-atopics	O
provides	O
independent	O
confirmation	O
of	O
the	O
presence	O
of	O
underlying	O
Th1-like	O
immunity	O
in	O
these	O
subjects	O
.	O
The	O
parallel	O
findings	O
in	O
neonatal	O
T	O
cells	O
suggest	O
that	O
the	O
same	O
approach	O
may	O
be	O
utilized	O
for	O
monitoring	O
the	O
progress	O
of	O
allergen-specific	O
Th1/Th2	O
memory	O
development	O
during	O
early	O
childhood	O
,	O
and	O
hence	O
in	O
assessment	O
of	O
risk	O
for	O
future	O
allergic	O
disease	O
.	O
Copyright	O
2001	O
S.	O
Karger	O
AG	O
,	O
Basel	O
The	O
heat	O
shock	O
response	O
reduces	O
myelin	O
oligodendrocyte	O
glycoprotein	O
-induced	O
experimental	O
autoimmune	O
encephalomyelitis	O
in	O
mice	O
.	O
The	O
stress	O
response	O
(	O
SR	O
)	O
can	O
block	O
inflammatory	O
gene	O
expression	O
by	O
preventing	O
activation	O
of	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappaB	B-protein
)	O
.	O
As	O
inflammatory	O
gene	O
expression	O
contributes	O
to	O
the	O
pathogenesis	O
of	O
demyelinating	O
diseases	O
,	O
we	O
tested	O
the	O
effects	O
of	O
the	O
SR	O
on	O
the	O
progression	O
of	O
the	O
demyelinating	O
disease	O
experimental	O
autoimmune	O
encephalomyelitis	O
(	O
EAE	O
)	O
.	O
EAE	O
was	O
actively	O
induced	O
in	O
C57BL/6	O
mice	O
using	O
an	O
encephalitogenic	O
myelin	O
oligodendrocyte	O
glycoprotein	O
(	O
MOG	O
(	O
35-55	O
)	O
)	O
peptide	O
.	O
Whole	O
body	O
hyperthermia	O
was	O
used	O
to	O
induce	O
a	O
heat	O
shock	O
response	O
(	O
HSR	O
)	O
in	O
immunized	O
mice	O
2	O
days	O
after	O
the	O
booster	O
MOG	O
(	O
35-55	O
)	O
peptide	O
injection	O
.	O
The	O
HSR	O
reduced	O
the	O
incidence	O
of	O
EAE	O
by	O
70	O
%	O
,	O
delayed	O
disease	O
onset	O
by	O
6	O
days	O
,	O
and	O
attenuated	O
disease	O
severity	O
.	O
The	O
HSR	O
attenuated	O
leukocyte	O
infiltration	O
into	O
CNS	O
assessed	O
by	O
quantitation	O
of	O
perivascular	O
infiltrates	O
,	O
and	O
by	O
reduced	O
staining	O
for	O
CD4	O
and	O
CD25	O
immunopositive	O
T-cells	O
.	O
T-cell	O
activation	O
,	O
assessed	O
by	O
the	O
production	O
of	O
interferon	B-protein
gamma	I-protein
(	O
IFNgamma	B-protein
)	O
in	O
response	O
to	O
MOG	O
(	O
35-55	O
)	O
,	O
was	O
also	O
decreased	O
by	O
the	O
HSR	O
.	O
The	O
HSR	O
reduced	O
inflammatory	O
gene	O
expression	O
in	O
the	O
brain	O
that	O
normally	O
occurs	O
during	O
EAE	O
,	O
including	O
the	O
early	O
increase	O
in	O
RANTES	O
(	O
regulated	O
on	O
activation	O
of	O
normal	O
T-cell	O
expressed	O
and	O
secreted	O
)	O
expression	O
,	O
and	O
the	O
later	O
expression	O
of	O
the	O
inducible	O
form	O
of	O
nitric	O
oxide	O
synthase	O
.	O
The	O
early	O
activation	O
of	O
transcription	B-protein
factor	I-protein
NF-kappaB	B-protein
was	O
also	O
blocked	O
by	O
the	O
HSR	O
.	O
The	O
finding	O
that	O
the	O
SR	O
reduces	O
inflammation	O
in	O
the	O
brain	O
and	O
the	O
clinical	O
severity	O
of	O
EAE	O
opens	O
a	O
novel	O
therapeutic	O
approach	O
for	O
prevention	O
of	O
autoimmune	O
diseases	O
.	O
In	O
vivo	O
detection	O
of	O
intracellular	O
signaling	O
pathways	O
in	O
developing	O
thymocytes	O
.	O
Information	O
regarding	O
the	O
intracellular	O
signaling	O
processes	O
that	O
occur	O
during	O
the	O
development	O
of	O
T	O
cells	O
has	O
largely	O
been	O
obtained	O
with	O
the	O
use	O
of	O
transgenic	O
mouse	O
models	O
,	O
which	O
although	O
providing	O
invaluable	O
information	O
are	O
time	O
consuming	O
and	O
costly	O
.	O
To	O
this	O
end	O
,	O
we	O
have	O
developed	O
a	O
novel	O
system	O
that	O
facilitates	O
the	O
in	O
vivo	O
analysis	O
of	O
signal	O
transduction	O
pathways	O
during	O
T-lymphocyte	O
development	O
.	O
This	O
approach	O
uses	O
reporter-plasmids	O
for	O
the	O
detection	O
of	O
intracellular	O
signals	O
mediated	O
by	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
or	O
cyclic	B-protein
AMP-dependent	I-protein
protein	I-protein
kinase	I-protein
.	O
Reporter-plasmids	O
are	O
transfected	O
into	O
thymocytes	O
in	O
fetal	O
thymic	O
organ	O
culture	O
by	O
accelerated	O
DNA/particle	O
bombardment	O
(	O
gene	O
gun	O
)	O
,	O
and	O
the	O
activation	O
of	O
a	O
signaling	O
pathway	O
is	O
determined	O
in	O
the	O
form	O
of	O
a	O
standard	O
luciferase	O
assay	O
.	O
Importantly	O
,	O
this	O
powerful	O
technique	O
preserves	O
the	O
structural	O
integrity	O
of	O
the	O
thymus	O
,	O
and	O
will	O
provide	O
an	O
invaluable	O
tool	O
to	O
study	O
how	O
thymocytes	O
respond	O
to	O
normal	O
environmental	O
stimuli	O
encountered	O
during	O
differentiation	O
within	O
the	O
thymic	O
milieu	O
.	O
Thus	O
,	O
this	O
method	O
allows	O
for	O
the	O
monitoring	O
of	O
signals	O
that	O
occur	O
in	O
a	O
biological	O
time	O
frame	O
,	O
such	O
as	O
during	O
differentiation	O
,	O
and	O
within	O
the	O
natural	O
environment	O
of	O
differentiating	O
cells	O
.	O
Core-binding	B-protein
factor	I-protein
beta	I-protein
(	O
CBFbeta	O
)	O
,	O
but	O
not	O
CBFbeta-smooth	O
muscle	O
myosin	O
heavy	O
chain	O
,	O
rescues	O
definitive	O
hematopoiesis	O
in	O
CBFbeta	O
-deficient	O
embryonic	O
stem	O
cells	O
.	O
Core-binding	B-protein
factor	I-protein
beta	I-protein
(	O
CBFbeta	O
)	O
is	O
the	O
non-DNA-binding	B-protein
subunit	I-protein
of	O
the	O
heterodimeric	O
CBFs	O
.	O
Genes	O
encoding	O
CBFbeta	B-protein
(	O
CBFB	O
)	O
,	O
and	O
one	O
of	O
the	O
DNA-binding	B-protein
CBFalpha	I-protein
subunits	I-protein
,	O
Runx1	O
(	O
also	O
known	O
as	O
CBFalpha2	B-protein
,	O
AML1	B-protein
,	O
and	O
PEBP2alphaB	O
)	O
,	O
are	O
required	O
for	O
normal	O
hematopoiesis	O
and	O
are	O
also	O
frequent	O
targets	O
of	O
chromosomal	O
translocations	O
in	O
acute	O
leukemias	O
in	O
humans	O
.	O
Homozygous	O
disruption	O
of	O
either	O
the	O
Runx1	B-protein
or	O
Cbfb	O
gene	O
in	O
mice	O
results	O
in	O
embryonic	O
lethality	O
at	O
midgestation	O
due	O
to	O
hemorrhaging	O
in	O
the	O
central	O
nervous	O
system	O
,	O
and	O
severely	O
impairs	O
fetal	O
liver	O
hematopoiesis	O
.	O
Results	O
of	O
this	O
study	O
show	O
that	O
Cbfb-deficient	O
mouse	O
embryonic	O
stem	O
(	O
ES	O
)	O
cells	O
can	O
differentiate	O
into	O
primitive	O
erythroid	O
colonies	O
in	O
vitro	O
,	O
but	O
are	O
impaired	O
in	O
their	O
ability	O
to	O
produce	O
definitive	O
erythroid	O
and	O
myeloid	O
colonies	O
,	O
mimicking	O
the	O
in	O
vivo	O
defect	O
.	O
Definitive	O
hematopoiesis	O
is	O
restored	O
by	O
ectopic	O
expression	O
of	O
full-length	O
Cbfb	O
transgenes	O
,	O
as	O
well	O
as	O
by	O
a	O
transgene	O
encoding	O
only	O
the	O
heterodimerization	O
domain	O
of	O
CBFbeta	O
.	O
In	O
contrast	O
,	O
the	O
CBFbeta	O
-	O
smooth	O
muscle	O
myosin	O
heavy	O
chain	O
(	O
SMMHC	O
)	O
fusion	B-protein
protein	I-protein
generated	O
by	O
the	O
inv	O
(	O
16	O
)	O
associated	O
with	O
acute	O
myeloid	O
leukemias	O
(	O
M4Eo	O
)	O
can	O
not	O
rescue	O
definitive	O
hematopoiesis	O
by	O
Cbfb-deficient	O
ES	O
cells	O
.	O
Sequences	O
responsible	O
for	O
the	O
inability	O
of	O
CBFbeta	O
-SMMHC	O
to	O
rescue	O
definitive	O
hematopoiesis	O
reside	O
in	O
the	O
SMMHC	O
portion	O
of	O
the	O
fusion	B-protein
protein	I-protein
.	O
Results	O
also	O
show	O
that	O
the	O
CBFbeta-SMMHC	O
fusion	O
protein	O
transdominantly	O
inhibits	O
definitive	O
hematopoiesis	O
,	O
but	O
not	O
to	O
the	O
same	O
extent	O
as	O
homozygous	O
loss	O
of	O
Runx1	B-protein
or	O
Cbfb	O
.	O
CBFbeta-SMMHC	O
preferentially	O
inhibits	O
the	O
differentiation	O
of	O
myeloid	O
lineage	O
cells	O
,	O
while	O
increasing	O
the	O
number	O
of	O
blastlike	O
cells	O
in	O
culture	O
.	O
The	O
latency	O
pattern	O
of	O
Epstein-Barr	O
virus	O
infection	O
and	O
viral	O
IL-10	B-protein
expression	O
in	O
cutaneous	O
natural	O
killer/T-cell	O
lymphomas	O
.	O
The	O
nasal	O
type	O
,	O
extranodal	O
natural	O
killer	O
or	O
T	O
(	O
NK/T	O
)	O
-cell	O
lymphoma	O
is	O
usually	O
associated	O
with	O
latent	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
infection	O
.	O
In	O
order	O
to	O
elucidate	O
the	O
EBV	O
gene	O
expression	O
patterns	O
in	O
vivo	O
,	O
we	O
examined	O
eight	O
patients	O
with	O
cutaneous	O
EBV-related	O
NK/T-cell	O
lymphomas	O
,	O
including	O
six	O
patients	O
with	O
a	O
NK-cell	O
phenotype	O
and	O
two	O
patients	O
with	O
a	O
T-cell	O
phenotype	O
.	O
The	O
implication	O
of	O
EBV	O
in	O
the	O
skin	O
lesions	O
was	O
determined	O
by	O
the	O
presence	O
of	O
EBV-DNA	B-protein
,	O
EBV-encoded	O
nuclear	O
RNA	O
(	O
EBER	O
)	O
and	O
a	O
clonality	O
of	O
EBV-DNA	O
fragments	O
containing	O
the	O
terminal	B-protein
repeats	I-protein
.	O
Transcripts	O
of	O
EBV-encoded	O
genes	O
were	O
screened	O
by	O
reverse	O
transcription-	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
,	O
and	O
confirmed	O
by	O
Southern	O
blot	O
hybridization	O
.	O
The	O
expression	O
of	O
EBV-related	B-protein
antigens	I-protein
was	O
examined	O
by	O
immunostaining	O
using	O
paraffin-embedded	O
tissue	O
sections	O
and	O
cell	O
pellets	O
of	O
EBV-positive	O
cell	O
lines	O
.	O
Our	O
study	O
demonstrated	O
that	O
all	O
samples	O
from	O
the	O
patients	O
contained	O
EBV	O
nuclear	O
antigen	O
(	O
EBNA	O
)	O
-1	O
mRNA	O
which	O
was	O
transcribed	O
using	O
the	O
Q	O
promoter	O
,	O
whereas	O
both	O
the	O
Q	O
promoter	O
and	O
another	O
upstream	O
promoter	O
(	O
Cp/Wp	O
)	O
were	O
used	O
in	O
EBV-positive	O
cell	O
lines	O
,	O
B95.8	O
,	O
Raji	O
and	O
Jiyoye	O
.	O
Latent	O
membrane	O
protein-1	O
(	O
LMP-1	B-protein
)	O
mRNA	O
was	O
detected	O
in	O
seven	O
of	O
eight	O
patients	O
and	O
all	O
cell	O
lines	O
,	O
whereas	O
EBNA-2	O
transcripts	O
were	O
found	O
only	O
